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Stanley, William C., Fabio A. Recchia, and Gary D. Lopaschuk. Myocardial Substrate Metabolism in the Normal
and Failing Heart. Physiol Rev 85: 1093–1129, 2005; doi:10.1152/physrev.00006.2004.—The alterations in myocardial
energy substrate metabolism that occur in heart failure, and the causes and consequences of these abnormalities, are
poorly understood. There is evidence to suggest that impaired substrate metabolism contributes to contractile
dysfunction and to the progressive left ventricular remodeling that are characteristic of the heart failure state. The
general concept that has recently emerged is that myocardial substrate selection is relatively normal during the early
stages of heart failure; however, in the advanced stages there is a downregulation in fatty acid oxidation, increased
glycolysis and glucose oxidation, reduced respiratory chain activity, and an impaired reserve for mitochondrial
oxidative flux. This review discusses 1) the metabolic changes that occur in chronic heart failure, with emphasis on
the mechanisms that regulate the changes in the expression of metabolic genes and the function of metabolic
pathways; 2) the consequences of these metabolic changes on cardiac function; 3) the role of changes in myocardial
substrate metabolism on ventricular remodeling and disease progression; and 4) the therapeutic potential of acute
and long-term manipulation of cardiac substrate metabolism in heart failure.
I. INTRODUCTION
Cardiovascular disease is the leading cause of death
and disability in the industrialized world, and although
there has been a reduction in mortality from acute myo-
cardial infarction over the last 30 years (215), there has
been a concomitant rise in mortality attributable to heart
failure (HF). The syndrome of HF was described by Hip-
pocrates over two millennia ago and presented as short-
ness of breath and peripheral edema (214, 215). Autopsies
performed in the 17th and 18th centuries revealed an
enlarged ventricular chamber and increased heart mass in
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HF patients (215). In the last century a myriad of struc-
tural and biochemical cardiac abnormalities were shown
to be associated with HF, from defects in mitochondria to
abnormal adrenergic signal transduction. At the end
stages of HF, the myocardium has low ATP content due to
a decreased ability to generate ATP by oxidative metab-
olism, and thus is unable to effectively transfer the chem-
ical energy from the metabolism of carbon fuels to con-
tractile work (12, 98, 213, 341). The consequences of
metabolic dysfunction in HF are poorly understood, but
there is growing evidence to support the concept that the
alterations in substrate metabolism seen in HF contribute
to contractile dysfunction and to the progression of left
ventricular (LV) remodeling that are characteristic of the
HF state.
Today HF is clinically defined as “a complex clinical
syndrome that can result from any structural or functional
cardiac disorder that impairs the ability of the ventricle to
fill with or eject blood” (179). Heart failure severely re-
duces exercise capacity and may or may not cause fluid
retention and pulmonary congestion. Many HF patients
have minimal edema or pulmonary congestion, thus the
term heart failure is preferred over the older term con-
gestive heart failure (179). Approximately two-thirds of
all HF patients have a history of ischemic heart disease,
and the remainder do not (215). HF presents as both
systolic and diastolic LV dysfunction, with diastolic dys-
function being more common in a patient with a history of
hypertension and/or diabetes in the absence of myocar-
dial ischemia (6, 14, 117). Current medical therapies for
HF are aimed at suppressing neurohormonal activation
(e.g., angiotensin converting enzyme inhibitors, angioten-
sin II receptor antagonists, -adrenergic receptor antago-
nists, and aldosterone receptor antagonists), and treating
fluid volume overload and hemodynamic symptoms (di-
uretics, digoxin, inotropic agents). These pharmacother-
apies for HF can improve clinical symptoms and slow the
progression of contractile dysfunction and expansion of
LV chamber volume; nevertheless, there is still progres-
sion, and the prognosis for even the optimally treated
patient remains poor (39, 63, 67). Moreover, there is re-
cent evidence that intense suppression of the neurohor-
monal systems does not provide further benefit compared
with more modest therapy (64, 385, 444). Thus there is a
need for novel therapies for HF, independent of the neu-
rohormonal axis, that can improve cardiac performance
and prevent or reverse the progression of LV dysfunction
and remodeling (38, 116, 381, 452).
Agents that act through optimization of cardiac sub-
strate metabolism are particularly attractive because they
could work additively with current therapies, while not
exerting negative hemodynamic effects (38, 116, 381,
431). Emerging evidence suggests that disturbances in
myocardial substrate utilization have adverse effects in
the failing myocardium (212, 213) and that shifting the
substrate preference of the heart away from fatty acids
towards carbohydrate oxidation can improve pump func-
tion and slow the progression of HF (23, 27, 28, 38, 53, 116,
428). Almost a century ago the observation was made that
acute ingestion of cane sugar relieved symptoms in pa-
tients with cardiac dysfunction, presumably of ischemia
origin (45, 140). The optimization of cardiac substrate
metabolism to improve cardiac function and slow pro-
gression in HF, without causing any direct negative he-
modynamic or inotropic effects, remains a conceptually
attractive therapeutic approach (38). To date, the role of
myocardial substrate metabolism in the natural history of
HF has not been thoroughly evaluated. Human, canine,
and rodent studies show that in late-stage failure there is
downregulation of myocardial fatty acid oxidation and
accelerated glucose oxidation (79, 332, 359, 362, 389).
However, the time course and the molecular mechanisms
for this switch in substrate oxidation are not well under-
stood (251, 388, 428).
It is important to keep in mind that HF is not a
specific disease, but rather an extremely complex syn-
drome that is dependent on etiology, duration, underlying
coronary artery disease and ischemia, endothelial dys-
function, and the co-occurrence of complicating disorders
such as diabetes, hypertension, and obesity. In Europe
and North America, 20–30% of HF patients are diabetic,
which in itself greatly alters myocardial substrate use
(434, 449, 510) and affects the development of HF and LV
remodeling after myocardial infarction (424). There is
tremendous heterogeneity among the published data from
patients and animals models of HF that may be attributed
to the etiology, severity, and duration of HF and, in the
case of animal models, the species studied. Moreover,
studies in animal models demonstrate that the changes in
myocardial metabolism and cardiac function often occur
late in the development of HF. Thus one must use caution
in drawing generalities from a single time point or from a
single animal model. In addition, within a given failing
heart there is likely gross and micro heterogeneity in the
metabolic changes within the LV.
Despite these caveats and limitations, it remains of
fundamental importance to identify the abnormalities
in myocardial substrate metabolism that occur over the
course of the development and progression of HF, and
to understand the impact they have on left ventricular
function and remodeling. This review discusses 1) the
metabolic changes that occur in chronic HF, with em-
phasis on the mechanisms that regulate the changes in
the expression of metabolic genes and the function of
metabolic pathways; 2) the consequences of these
changes on cardiac function; 3) the role of changes in
myocardial substrate metabolism in ventricular remod-
eling and disease progression; and 4) the therapeutic
potential of acute and long-term manipulation of car-
diac energy metabolism in HF.
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It is important to note that this review focuses on
myocardial substrate metabolism in HF, and not on the
well-documented HF-induced abnormalities in the trans-
fer of energy from mitochondrial ATP to systolic and
diastolic work. The reader is referred to recent reviews on
this topic (98, 190, 477).
II. OVERVIEW OF MYOCARDIAL
SUBSTRATE METABOLISM
To understand myocardial metabolism in HF, it is
important to first have a solid understanding of myocar-
dial metabolism in the normal heart and to understand the
complex pathophysiology of HF. The reader is referred to
textbooks and reviews on myocardial metabolism (270,
331, 433, 448, 473) and the pathophysiology of HF (215).
A. Regulation of Metabolic Pathways in the Heart
Under nonischemic conditions almost all (95%) of
ATP formation in the heart comes from oxidative phos-
phorylation in the mitochondria (Fig. 1), with the remain-
der derived from glycolysis and GTP formation in the
citric acid cycle. The heart has a relatively low ATP
content (5 mol/g wet wt) and high rate of ATP hydrolysis
(0.5 mol · g wet wt1 · s1 at rest), thus there is
complete turnover of the myocardial ATP pool approxi-
mately every 10 s under normal conditions (188, 331).
Approximately 60–70% of ATP hydrolysis fuels contrac-
tile shortening, and the remaining 30–40% is primarily
used for the sarcoplasmic reticulum Ca2-ATPase and
other ion pumps (128, 440). In the healthy heart the rate of
oxidative phosphorylation is exquisitely linked to the rate
of ATP hydrolysis so that ATP content remains constant
even with large increases in cardiac power (17, 18, 153),
such as occur during intense exercise or acute catechol-
amine stress. Mitochondrial oxidative phosphorylation is
fueled with energy from electrons that are transferred
from carbon fuels by dehydrogenation reactions that gen-
erate NADH and FADH2 produced primarily in the fatty
acid -oxidation pathway, the citric acid cycle, and to a
lesser extent from the pyruvate dehydrogenase reaction
and glycolysis (Figs. 1 and 2). There is a stoichiometric
link between the rate of oxidation of carbon fuels, NADH
and FADH2 reduction, flux through the electron transport
chain, oxygen consumption, oxidative phosphorylation,
ATP hydrolysis, actin-myosin interaction, and external
contractile power produced by the heart (Figs. 1 and 2).
Thus an increase in contractile power results in a con-
comitant increase in all of the components in the system.
The regulation of myocardial metabolism is linked to
arterial carbon substrate concentration, hormone concen-
trations, coronary flow, inotropic state, and the nutri-
tional status of the tissue (331, 433, 448). The citric acid
cycle is fueled by acetyl-CoA formed from decarboxyl-
ation of pyruvate and from -oxidation of fatty acids (Fig.
2). The reducing equivalents (NADH and FADH2) that are
generated by either the dehydrogenases of glycolysis, the
oxidation of lactate and pyruvate and fatty acid -oxida-
tion, or the citric acid cycle deliver electrons to the elec-
tron transport chain, resulting in ATP formation by oxi-
dative phosphorylation. In the healthy heart the rates of
flux through the metabolic pathways linked to ATP
generation are set by the requirement for external
power generated by the myocardium and the rate of
ATP hydrolysis.
The rates of flux through the various metabolic path-
ways are controlled by both the degree of expression of
key metabolic proteins (enzymes and transporters) and
complex pathway regulation that is exerted by both allo-
steric regulation of enzymes and substrate/product rela-
tionships. The metabolic machinery in the heart is de-
signed to generate large amounts of ATP to support high
rates of external cardiac power. At maximal cardiac work
loads in vivo this metabolic machinery consumes oxygen
at 80–90% of the mitochondrial capacity for electron
transport chain flux and oxygen consumption (315). At
rest, however, the heart operates at 15–25% of its max-
imal oxidative capacity, thus the expression or maximal
activity of a key metabolic enzyme can be greatly reduced
or increased without necessarily affecting ATP produc-
tion or flux through the relevant pathway under resting
conditions (106, 107). This is because flux through meta-
bolic pathways can be rapidly turned on or off by alloste-
ric modification of regulatory enzymes, changes in the
FIG. 1. Linkages between cardiac power,
ATP hydrolysis, oxidative phosphorylation, and
NADH generation by dehydrogenases in metab-
olism. SR, sarcoplasmic reticulum.
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concentration of inhibitory or stimulatory metabolites, or
translocation of metabolic proteins to their site of func-
tion. These mechanisms allow for the rapid adaptation to
acute stresses such as exercise, ischemia, or fasting.
B. Carbohydrate Metabolism
In the well-perfused heart, 60 –90% of the acetyl-
CoA comes from -oxidation of fatty acids, and 10 – 40%
comes from the oxidation of pyruvate (126, 433, 492,
493, 495) that is derived in approximately equal
amounts from glycolysis and lactate oxidation (126,
433, 492, 493, 495). The glycolytic pathway converts
glucose 6-phosphate and NAD to pyruvate and NADH
and generates two ATP for each molecule of glucose.
The NADH and pyruvate formed in glycolysis are either
shuttled into the mitochondrial matrix to generate CO2
and NAD and complete the process of aerobic oxida-
tive glycolysis or converted to lactate and NAD in the
cytosol (nonoxidative glycolysis).
The healthy nonischemic heart is a net consumer of
lactate even under conditions of near-maximal cardiac
power (204, 292, 426). The myocardium becomes a net
lactate producer only when there is accelerated glycolysis
in the face of impaired oxidation of pyruvate, such as
occurs with ischemia (85, 331, 433) or poorly controlled
diabetes (15, 145, 434). There is a high rate of bidirec-
tional lactate transmembrane flux and conversion to pyru-
vate (125, 141, 204, 293, 492, 493). Lactate transport across
the cardiac sarcolemma is facilitated by the monocar-
boxylic acid transporter-1 (MCT-1) (Fig. 2; Refs. 118, 203).
Glycolytic substrate is derived from exogenous glu-
cose and glycogen stores. Glucose transport into cardio-
myocytes is regulated by the transmembrane glucose gra-
dient and the content of glucose transporters in the sar-
colemma (mainly GLUT-4, and to a lesser extent GLUT-1)
(Fig. 2). There is a translocation of glucose transporters
from intracellular vesicles to the sarcolemmal membrane
in response to insulin stimulation, increased work de-
mand, or ischemia (433, 506, 507), which increases the
membrane capacitance for glucose transport and the rate
of glucose uptake. Translocation of GLUT-4 into the sar-
colemma is also stimulated by activation of AMP-acti-
vated protein kinase (AMPK) (379, 506), which occurs
during exercise stress in the rat heart (71). Mice with
cardiac-specific overexpression of a dominant negative
mutant of AMPK have depressed rates of glucose uptake
(499), suggesting a critical role for AMPK in regulating
basal glucose uptake in the heart. Russell et al. (380)
recently demonstrated that transgenic mice expressing
inactive AMPK have normal GLUT4 expression as well
as baseline and insulin-stimulated cardiac glucose up-
take, but fail to increase glucose uptake and glycolysis
during ischemia (380), illustrating a key role for AMPK
in mediating insulin-independent ischemia-induced glu-
cose uptake.
An additional source of glucose 6-phosphate for the
heart is intracellular glycogen stores. The glycogen pool
in the heart is relatively small (30 mol/g wet wt com-
pared with 150 mol/g wet wt in skeletal muscle) (35,
331, 429) and has a relatively rapid turnover despite stable
tissue concentrations (155). Glycogen concentrations are
increased by an elevated supply of exogenous substrate
and/or hyperinsulinemia (235, 246, 433), and glycogenol-
ysis is activated by adrenergic stimulation (e.g., increases
in cAMP and Ca2), a fall in the tissue content of ATP, and
a rise in inorganic phosphate such as occur with ischemia
or intense exercise (133, 176, 433). Recently, there has
been considerable interest focused on the role of AMPK in
regulating glycogen content in the heart (9, 71, 499). Con-
stitutively active AMPK due to a mutation in a regulatory
subunit of the enzyme was recently shown to be associ-
FIG. 2. The pathways and regulatory
points of myocardial substrate metabolism.
CPT-I, carnitine palmitoyltransferase-I; FAT,
fatty acid transporter/CD36; G 6-P, glucose
6-phosphate; GLUT, glucose transporters;
MCT, monocarboxylic acid transporters;
PDH, pyruvate dehydrogenase.
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ated with glycogen accumulation and hypertrophic car-
diomyopathy (8, 9, 134). In contrast, acute activation of
AMPK has been shown to activate glycogenolysis (267,
346). Clinically, patients with a mutation in the gamma-2
regulatory subunit of AMPK have Wolff-Parkinson-White
syndrome and conduction system disease in the absence
of cardiac hypertrophy (134, 135, 330), although the cel-
lular mechanisms linking abnormal AMPK activity and the
electrophysiological abnormalities are unclear.
Phosphofructokinase-1 (PFK-1) is a key regulatory
enzyme in the glycolytic pathway and catalyzes the first
irreversible step (Fig. 3). PFK-1 utilizes ATP to produce
fructose 1,6-bisphosphate and is activated by ADP, AMP,
and Pi and inhibited by ATP, thus accelerating flux
through glycolysis when the phosphorylation potential
falls. PFK-1 can also be inhibited by fructose 1,6-bisphos-
phate and by a fall in pH. The extent of [H] inhibition of
PFK-1 depends on ATP levels, with the inhibition being
greatest when ATP levels are high (see Ref. 209 for re-
view). As AMP accumulates, the sensitivity of PFK-1 to
[H] decreases. PFK-1 can also be stimulated by fructose
2,6-bisphosphate (F2,6BP), which is a feedforward activa-
tor of the enzyme (177). Citrate is a negative allosteric
regulator of PFK-1 and links changes in mitochondrial
oxidative metabolism to glycolysis. Accumulation of ci-
trate was first proposed by Philip Randle to contribute to
the decrease in glycolysis that occurs in various tissues
when fatty acid oxidation increases (119, 325, 351, 352).
F2,6BP is a potent stimulator of PFK-1 and is formed
from fructose 6-phosphate by the bifunctional enzyme phos-
phofructo-2-kinase/fructose-2,6-bisphosphatase (PFK-2)
(Fig. 3) (176, 177). Synthesis of F2,6BP by PFK-2 results in
an activation of PFK-1. F2,6BP increases PFK-1 by in-
creasing the affinity of the enzyme for fructose 6-phos-
phate and by decreasing the inhibitory effects of ATP on
PFK-1. The production of F2,6BP itself is highly regulated
(Fig. 3), with PFK-2 activity controlled by three main
mechanisms: 1) by allosteric modulation of PFK-2 activ-
ity, 2) by phosphorylation control of PFK-2 activity, and
3) by transcriptional control of enzyme activity (249, 368).
PFK-2 is allosterically inhibited by citrate, which by de-
creasing F2,6BP levels is a second mechanism by which
citrate can inhibit PFK-1 activity. A number of hormones
that activate glycolysis, including insulin, glucagon, epineph-
rine, norepinephrine, and thyroid hormone, exert phosphor-
ylation control on PFK-2 (209). In addition, AMPK can also
phosphorylate PFK-2 (175, 288). Phosphorylation and ac-
tivation of PFK-2 by AMPK is an attractive mechanism to
explain AMP-induced acceleration of glycolysis.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
catalyzes the conversion of glyceraldehyde 3-phosphate
to 1,3-diphosphoglycerate and produces the NADH mole-
cules that originate from glycolysis. GAPDH is a major
regulatory step in the glycolytic pathway, since the accu-
mulation of NADH within the cytoplasm of cells inhibits
the GAPDH reaction rate. In contrast, an increase in
NAD activates GAPDH activity. High concentrations of
lactate inhibit the regeneration of NAD from NADH and
thus reduce the flux through GAPDH, as do high concen-
trations of the product of the reaction, 1,3-diphosphoglyc-
erate. During myocardial ischemia, an accumulation of
lactate and NADH can result in GAPDH becoming the
main rate-controlling reaction in glycolysis. For instance,
severe ischemia in heart muscle will result in the cessa-
tion of oxidative metabolism, and the subsequent accu-
mulation of NADH in the cytosol, and accumulation of
lactate within the cell.
Cell fraction studies demonstrate that glycolytic en-
zymes are clustered near the sarcoplasmic reticulum and
sarcolemma (103, 344, 486, 500), suggesting that glyco-
lytic reactions are not distributed throughout the cytosol,
but rather occur in a subdomain outside around the pe-
rimeter of the cardiomyocyte. Further support for this
concept comes from in silico studies of the transition
from normal to ischemic conditions, which shows that
compartmentation of glycolysis to 10% of the cytosolic
space is required to simulate the burst of glycolysis that
occurs with the onset of ischemia in vivo (519). Studies
assessing the effect of inhibition of glycolysis suggest that
glycolytically generated ATP is perferentially used by the
sarcoplasmic reticulum to fuel Ca2 uptake (103) and by
the sarcolemma to maintain ion homeostatis (487, 488).
Furthermore, inhibition of glycolysis impairs relaxation in
ischemic and postischemic reperfused myocardium, sug-
gesting that glycolytic ATP may be essential for optimal
diastolic relaxation (197, 240, 486).
The pyruvate formed from glycolysis has three main
fates: conversion to lactate, decarboxylation to acetyl-
CoA, or carboxylation to oxaloacetate or malate. Pyru-
FIG. 3. Regulation of phosphofructokinase-1 (PFK-1) by PFK-2 and
fructose 2,6-bisphosphate. PKA, protein kinase A; PKC, protein kinase C;
PI3K, phosphatidylinositol 3-kinase.
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vate decarboxylation is the key irreversible step in carbo-
hydrate oxidation and is catalyzed by pyruvate dehydro-
genase (PDH) (Fig. 4) (350), a multienzyme complex
located in the mitochondrial matrix. PDH is inactivated by
phosphorylation on the E1 subunit of the enzyme complex
by a specific PDH kinase (PDK) and is activated by de-
phosphorylation by a specific PDH phosphatase (219, 350,
355, 491) (Fig. 4). PDK is inhibited by pyruvate and by
decreases in the acetyl-CoA/free CoA and NADH/NAD
ratios (219, 355, 490) (Fig. 4). There are four isoforms of
PDK; PDK4 is the predominant form in heart, and its
expression is rapidly induced by starvation, diabetes, and
peroxisome proliferater activated receptor- (PPAR) li-
gands (36, 150, 496), suggesting that its expression is
controlled by the activity of the PPAR promoter system
(see sect. IIIA). High circulating lipid and intracellular
accumulation of long-chain fatty acid moieties, such as
occur with fasting or diabetes, enhance PPAR-mediated
expression of PDK4, resulting in greater phosphorylation
inhibition of PDH and less oxidation of pyruvate derived
from glycolysis and lactate oxidation (172, 496). The PDH
complex also contains a PDH phosphatase that dephos-
phorylates and activates PDH. The activity of PDH phos-
phatase is increased by Ca2 and Mg2 (295). Adrenergic
stimulation of the heart increases the cytosolic Ca2 tran-
sient, and mitochondrial Ca2 concentration results in
activation of PDH (294, 296), thus explaining the activa-
tion of PDH and greater pyruvate oxidation in response to
a -adrenergic-induced increase in cardiac power (66,
126, 139, 294), despite no changes in any of the activators
of PDK4 activity (416).
The oxidation of glucose and pyruvate and the activ-
ity of PDH in the heart are decreased by elevated rates of
fatty acid oxidation, such as occur if plasma levels of free
fatty acids (FFA) are elevated. In addition, pyruvate oxi-
dation is enhanced by suppression of fatty acid oxidation,
as observed with a decreased plasma FFA levels, or by a
direct inhibition of fatty acid oxidation (61, 164, 165, 235,
270, 410, 433). As discussed above, high rates of fatty acid
oxidation also inhibit PFK-1 and PFK-2 (and thus glycol-
ysis) via an increase in cytosolic citrate concentration
(Fig. 4) This “glucose-fatty acid cycle” was first described
by Philip Randle and colleagues in the 1960s (119, 353,
354), and thus is generally referred to as the “Randle
cycle.” The maximal rate of pyruvate oxidation at any
given time is set by the degree of phosphorylation of PDH;
however, the actual flux is determined by the concentra-
tions of substrates and products in the mitochondrial
matrix as these control the rate of flux through the active
dephosphorylated complex (148).
In addition to lactate formation and oxidation by
PDH, pyruvate enters the citric acid cycle (CAC) via
carboxylation to either malate or oxaloacetate (442). This
reaction is “anaplerotic” (127, 231) and acts to maintain
the pool size of CAC intermediates and CAC function in
the face of the small but constant loss of CAC intermedi-
ates through efflux of citrate and, to a lesser extent,
succinate and fumarate from the heart (55, 69, 102, 244,
456, 458, 479). Pyruvate carboxylation accounts for
2–6% of the CAC flux under normal flow aerobic con-
ditions (69, 336), and it is reduced relative to CAC flux
when MV˙O2 is reduced in acutely hibernating swine myo-
cardium (335). Another source of anaplerotic flux into the
CAC is via transamination of glutamate to -ketogluta-
rate, as demonstrated by the low but persistent uptake of
glutamate in the human heart (318, 457–459). Studies
using 13C-labeled glutamate in perfused rat hearts suggest
that conversion to -ketoglutarate may be critical for the
FIG. 4. Regulation of the oxidation of
glucose and lactate by pyruvate dehydro-
genase (PDH). The activity of PDH is in-
hibited by product inhibition from acetyl-
CoA and NADH (dashed arrows), and by
phosphorylation by PDH kinase and de-
phosphorylation by PDH phosphatase.
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regulation of the initial span of the CAC, particularly
during ischemia (68). Another anaplerotic pathway is the
formation of succinyl-CoA from propionyl-CoA that is
generated from the terminal three carbons of odd chain
length fatty acids (127, 258, 284, 290, 367). Plasma levels
of propionate and other odd-chain-length fatty acids are
low in humans; thus this is not a major pathway under
normal conditions. However, a recent small clinical study
in patients with deficiencies in long-chain fatty acid oxi-
dation have clinical improvement and reversal of cardiac
dysfunction with dietary supplementation with heptano-
ate, perhaps due to increased anaplerosis (369).
Pyruvate can also contribute to anaplerosis by
transamination with glutamate to form alanine and the
CAC intermediate -ketoglutarate. The rate of alanine
output by the myocardium is relatively low in dogs, pigs,
and humans (15, 142, 305, 412, 459, 495) and is unaffected
by acute ischemia (142) or when glycolysis is accelerated
with hyperinsulinemia and hyperglycemia (495). Studies
in stable coronary artery disease patients showed ele-
vated alanine output compared with healthy people (318).
C. Fatty Acid Metabolism
The rate of fatty acid uptake by the heart is primarily
determined by the concentration of nonesterified fatty
acids in the plasma (32, 270, 494), which can vary over a
fourfold range in healthy humans during the course of the
day (from0.2 to 0.8 mM). Under conditions of metabolic
stress, such as ischemia, diabetes, or starvation, plasma
FFA concentrations can increase to much higher levels
(1.0 mM) (271). Free fatty acids are highly hydrophobic
and are never truly free in vivo but rather are associated
with proteins or covalently bound to coenzyme A or car-
nitine. They are transported in the plasma in the nones-
terified form attached to albumin, or covalently bound in
triglyceride, contained with chylomicrons or very-low-
density lipoproteins. Plasma fatty acid concentration is
regulated by their net release from triglycerides in adipo-
cytes, which reflects the net balance between triglyceride
breakdown by hormone-sensitive lipase and synthesis by
glycerolphosphate acyltransferase (270). Hormone-sensi-
tive lipase is activated by catecholamines and inhibited by
insulin. Thus, with fasting, when insulin is low and cat-
echolamines are high, the plasma FFA concentration is
elevated, resulting in a high rate of fatty acid uptake and
oxidation by the heart. Fatty acids are also released from
triglyceride in chylomicrons and in very-low-density li-
poproteins that are hydrolyzed by lipoprotein lipase
bound to the outside of capillary endothelial cells and
cardiomyocytes (13, 306, 501, 505).
Fatty acids enter the cardiomyocyte by either passive
diffusion or by protein-mediated transport across the sar-
colemma (Fig. 5) (473) involving either a fatty acid trans-
locase (FAT), or a plasma membrane fatty acid binding
protein (FABPpm) (131, 401, 473). A specific 88-kDa FAT
protein called CD36 is abundantly expressed in skeletal
and cardiac muscle and appears to be the predominant
form of FAT in the heart (401, 473). People with mutations
in the CD36 gene have lower rates of uptake of the
long-chain fatty acid analog 123I-15-(p-iodophenyl)-3-
methylpentadecanoic acid compared with normal people
(226), suggesting that CD36 partially regulates the rate of
myocardial fatty acid uptake in humans. Once transported
FIG. 5. Schematic depiction of myo-
cardial fatty acid metabolism. ACC,
acetyl-CoA carboxylase; AMPK, AMP-ac-
tivated protein kinase; CAT, carnitine
acyltranslocase; CPT-I, carnitine palmi-
toyltransferase-I; CPT-II, carnitine palmi-
toyltransferase-II; FABPPM, plasma mem-
brane fatty acid binding protein; FAT,
fatty acid transporter; FFA, free fatty ac-
ids; LPL, lipoprotein lipase; MCD, malo-
nyl-CoA decarboxylase; TG, triglyceride;
VLDL, very-low-density lipoproteins.
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across the sarcolemma, the nonesterified fatty acids bind
to FABP and are then activated by esterification to fatty
acyl-CoA by fatty acyl-CoA synthase (FACS) (Fig. 5).
FABPs are abundant in the cytosol and appear to be the
primary intracellular carrier of nonesterified fatty acids.
Recent studies show that there are FABP and FACS pro-
tein associated with CD36 on the cytosolic side of the
sarcolemmal membrane, thus raising the possibility that
fatty acids transported across the membrane can also be
immediately esterified to fatty acyl-CoA (401). Inhibitable
fatty acid transport is greater in electrically stimulated
isolated cardiomyocytes compared with unstimulated
conditions, suggesting that there is a translocation of
FAT/CD36 into the sarcolemma from an intracellular site
in response to contraction or increased energy demand
(277–279). A similar phenomenon was observed in re-
sponse to insulin stimulation (279). Translocation of FAT/
CD36 has not been demonstrated in response to increased
cardiac energy expenditure or insulin stimulation in the
intact heart (277); thus it remains to be seen if transloca-
tion of FAT/CD36 regulates myocardial fatty acid trans-
port under physiologically relevant conditions.
The product of FACS, long-chain fatty acyl-CoA, can
either be esterified to triglyceride by glycerolphosphate acyl-
transferase (65, 270, 473) or converted to long-chain fatty
acylcarnitine by carnitine palmitoyltransferase I (CPT-I)
(Fig. 5) (270). Studies in normal humans, coronary artery
disease patients, and large animals demonstrate that 70–90%
of the [14C]- or [3H]oleate or palmitate that is taken up by the
heart is immediately released into the venous effluent as
14CO2 or
3H2O (51, 54, 245, 494). This suggests that in the
healthy normal heart 70–90% of the fatty acids entering the
cell are converted to acylcarnitine and immediately oxi-
dized, and 10–30% enter the intracardiac triglyceride pool
(270, 391, 392). The myocardial triglyceride pool is an im-
portant source of fatty acids, with the rate of lipolysis of
myocardial triglycerides and its contribution to overall myo-
cardial ATP production being inversely related to the con-
centration of exogenous fatty acids (72, 75, 339, 391). Tri-
glyceride turnover can be rapidly accelerated by adrenergic
stimulation (73, 74, 76, 138, 139, 233, 443) and is increased in
uncontrolled diabetes (339, 393) and during reperfusion of
ischemic hearts (392).
Fatty acid -oxidation occurs primarily in the mito-
chondria and to a small extent in peroxisomes (238, 409).
The primary products of fatty acid oxidation are NADH,
FADH2, and acetyl-CoA (Fig. 5). Before mitochondrial
-oxidation, the cytoplasmic long-chain acyl-CoA must
first be transported into the mitochondrial matrix. Be-
cause the inner mitochondrial membrane is not perme-
able to long-chain acyl-CoA, the long-chain fatty acyl moi-
ety is transferred from the cytosol into the matrix by a
carnitine-dependent transport system (220, 270). First,
CPT-I catalyzes the formation of long-chain acylcarnitine
from long-chain acyl-CoA in the compartment between
the inner and outer mitochondrial membranes. Next, car-
nitine acyltranslocase transports this long-chain acylcar-
nitine across the inner mitochondrial membrane in ex-
change for free carnitine. Lastly, carnitine palmitoyltrans-
ferase II (CPT-II) regenerates long-chain acyl CoA in the
mitochondrial matrix (Fig. 5). Of the three enzymes in-
volved in the transmitochondrial membrane transport,
CPT-I serves the key regulatory role in controlling the rate
of fatty acid uptake by the mitochondria (220, 270).
The activity of CPT-I is strongly inhibited by malonyl-
CoA, which binds to CPT-I on the cytosolic side of the
enzyme (Fig. 5) (220, 302, 513). There are two isoforms of
CPT-I: CPT-I predominates in the liver, and CPT-I is the
main isoform in the heart (300, 302). CPT-I is 30-fold more
sensitive to malonyl-CoA inhibition than is CPT-I (300, 302,
485). Malonyl-CoA is a key physiological regulator of fatty
acid oxidation in the heart. A fall in malonyl-CoA increases
fatty acid uptake and oxidation (2, 143, 236), and an increase
suppresses fatty acid oxidation (390, 430). Malonyl-CoA is
formed from the carboxylation of acetyl-CoA by acetyl-CoA
carboxylase (ACC) (137, 143, 145, 236, 375, 390, 454) and has
a rapid rate of turnover in the heart (364, 366). Most of the
acetyl-CoA in cardiomyocytes resides in the mitochondria
(185); however, CPT-I activity is regulated by malonyl-CoA
that is formed from carboxylation of extramitochondrial
acetyl-CoA. There is indirect evidence to suggest that extra-
mitochondrial acetyl-CoA is derived from citrate via the
ATP-citrate lyase reaction (345, 395) and from the export for
mitochondrial acetyl-CoA as acetylcarnitine (281, 390). More
recently, results from studies with 13C-labeled substrates
and isotopomer analysis of malonyl-CoA provided direct
evidence that in the perfused rat heart malonyl-CoA is de-
rived from acetyl-CoA formed in peroxisomal -oxidation of
long-chain fatty acids (365). Furthermore, the data were
consistent with long-chain fatty acids undergoing only a few
cycles of -oxidation in peroxisomes, followed by the gen-
eration of C12 and C14 fatty acyl-CoAs that are subsequently
oxidized to acetyl-CoA in the mitochondria (365).
The activity of ACC is inhibited by phosphorylation
by AMPK (236, 319, 394); thus activation of AMPK can
result in reduced malonyl-CoA formation and accelera-
tion of fatty acid oxidation (94, 95). It was recently shown
there is an increase in AMPK activity in rats with LV
hypertrophy produced by aortic banding (462), although
the metabolic consequences of this activation are unclear.
As discussed in section IIB, mutations in the gamma-2
regulatory subunit of AMPK result in glycogen accumula-
tion and hypertrophic cardiomyopathy in mice (8, 9) and
Wolffe-Parkinson-White syndrome in patients (135, 135,
330). To our knowledge, the effect of HF on AMPK ex-
pression and activity are not known. As discussed above,
AMPK activation in the heart also stimulates glucose
transporter translocation and glucose uptake (71, 379,
499); thus activation of AMPK can effect an increase in
both carbohydrate and fatty acid metabolism. Thus, when
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the metabolic rate of the heart is increased, as occurs
during exercise, increased AMPK activity would increase
acetyl-CoA production from both carbohydrates and lip-
ids, and thus ensure an adequate supply of substrate to
the mitochondria (71).
The degradation of malonyl-CoA is regulated by the
activity of malonyl-CoA decarboxylase (MCD), which
converts malonyl-CoA back to acetyl-CoA and CO2 in the
cytosol and mitochondrial (Fig. 5) (93, 146, 221, 225, 394).
In general, situations where MCD activity is high results in
low myocardial malonyl-CoA content and high rates of
fatty acid oxidation (48, 92, 93). We have recently shown
that pharmacological inhibition of MCD activity increases
myocardial malonyl-CoA content, and (93) MCD activity
regulates fatty acid oxidation. In addition, inhibition of
MCD activity reduces malonyl-CoA turnover (366) and
increases glucose oxidation under aerobic, ischemic, and
postischemic conditions and improves postischemic re-
covery of contractile function (93), as has been previously
observed with CPT-I inhibitors (163, 164, 427). An in-
crease in cardiac power induced by -adrenergic receptor
stimulation results in a fall in myocardial malonyl-CoA
content and accelerated fatty acid uptake and oxidation;
however, this effect is not due to activation of AMPK or
reduced ACC activity (137, 143) but has been associated
with a reduction in the Km of MCD(137), although this has
not been a consistent finding (366).
Once taken up by the mitochondria, fatty acids undergo
-oxidation, a process that repeatedly cleaves off two car-
bon acetyl-CoA units, generating NADH and FADH2 in the
process (Fig. 5). The -oxidation process involves four re-
actions, with specific enzymes for each step, and each reac-
tion has specific enzymes for long-, medium-, and short-
chain length fatty intermediates (30, 32). The first step is
catalyzed by acyl-CoA dehydrogenase, followed by 2-enoyl-
CoA hydratase, and then 3-hydroxyacyl-CoA dehydroge-
nase. The final step is 3-ketoacyl-CoA thiolase (3-KAT),
which regenerates acyl-CoA for another round of -oxida-
tion and releases acetyl-CoA for the citric acid cycle. Acyl-
CoA dehydrogenase and 3-hydroxyacyl-CoA dehydrogenase
generate FADH2 and NADH, respectively, and the acetyl-
CoA formed from -oxidation generates more NADH and
FADH2 in the CAC.
D. Ketone Body Metabolism
The heart extracts and oxidizes ketone bodies (-
hydroxybutyrate and acetoacetate) in a concentration-
dependent manner (56, 114, 152, 441). Plasma ketone
bodies are formed from fatty acids in the liver, and the
arterial plasma concentration is normally very low, thus
they are normally a minor substrate for the myocardium.
During starvation or poorly controlled diabetes, plasma
ketone body concentrations are elevated secondary to
low insulin and high fatty acids, and they become a major
substrate for the myocardium (15, 145). As with fatty
acids, the uptake and oxidation of glucose and lactate are
inhibited by elevated plasma ketone bodies (32, 436, 441,
467), with the inhibitory effect presumably mediated
through product inhibition on PDH (see sect. IIF).
Oxidation of ketone bodies inhibits myocardial fatty
acid oxidation (56, 114, 152, 243, 261, 436, 474). Diabetic
myocardium has a high rate of -hydroxybutyrate uptake
and relatively low rates of fatty acid uptake (145), sug-
gesting that in diabetic patients elevated plasma ketone
concentrations can act to inhibit fatty acid uptake and
oxidation. Clinical studies demonstrate that HF results in
an increase in plasma ketone body concentration that
appears to be secondary to elevated fatty acid levels
(264–266); however, data on myocardial ketone body me-
tabolism have not been reported from animals or patients
with HF. The biochemical mechanisms responsible for
inhibition of fatty acid -oxidation by ketone bodies are
not well understood, but do not appear to be related to
changes in malonyl-CoA or the acetyl-CoA-to-free CoA
ratio (436). Elevated rates of -hydroxybutyrate and ace-
toacetate oxidation could inhibit fatty acid -oxidation by
increasing the intramitochondrial ratio of NADH to
NAD, which would inhibit the ketoacyl-CoA dehydroge-
nase step of the fatty acid -oxidation spiral (219, 238).
Hasselbaink et al. (152) recently showed that palmitate
oxidation was significantly enhanced in isolated cardio-
myocytes from streptozotocin diabetic rats in the ab-
sence of acetoacetate; however, when measurements
were made with the addition of ketone bodies, the rate
of palmitate oxidation was not affected by diabetes.
They also noted greater fatty acid uptake in the myo-
cytes from diabetic rats and suggested that ketone-
induced impairment of fatty acid oxidation might be
responsible for the greater triglyceride storage in the
heart with diabetes (82).
E. Interregulation of Fatty Acid
and Carbohydrate Oxidation
The primary physiological regulator of flux through
PDH and the rate of glucose oxidation in the heart is the
rate of fatty acid oxidation (Fig. 4). High rates of fatty acid
oxidation inhibit PDH activity via an increase in mito-
chondrial acetyl-CoA/free CoA and NADH/ NAD, which
activates PDH kinase causing phosphorylation and inhi-
bition of PDH (Fig. 4). In addition, in isolated heart mito-
chondria elevated rates of fatty acid oxidation inhibit flux
through PDH at a given PDH phosphorylation state (148).
Conversely, inhibition of fatty acid oxidation increases
glucose and lactate uptake and oxidation by 1) decreasing
citrate levels and inhibition of PFK and 2) lowering acetyl-
CoA and/or NADH levels in the mitochondrial matrix,
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thereby relieving the inhibition of PDH (165) (Figs. 4 and
5). This effect has been demonstrated with 1) lowering
plasma free fatty acid concentration by administering an
inhibitor of lipolysis in adipocytes (229, 230, 245, 438), 2)
inhibition of CPT-I (51, 164, 165), 3) inhibition of malonyl-
CoA decarboxylase (which elevates malonyl-CoA content
and inhibits CPT-I activity)(93, 366), and 4) direct inhibi-
tors of fatty acid -oxidation (207, 297). It is important to
note that partial inhibitors of myocardial fatty acid oxi-
dation have been shown to lessen ischemic dysfunction
and tissue damage in animal models of ischemia and
reperfusion and have clear benefits in clinical trials in
patients with chronic stable angina (26, 50, 78, 195, 340,
406, 445); this effect has been attributed to increased
pyruvate oxidation and less lactate accumulation and ef-
flux, and decreased proton accumulation (29, 164, 165,
427, 433).
F. Effects of Substrate Selection on Contractile
Function and Efficiency
Several lines of evidence suggest that the contractile
performance of the heart at a given MV˙O2 is greater when
the heart is oxidizing more glucose and lactate, and less
fatty acids (47, 183, 227, 232, 243, 309, 310, 421). Studies in
isolated rat hearts demonstrate that the mechanical
power of the LV is less at a given rate of oxygen consump-
tion when fatty acids rather than glucose are the sole
exogenous substrate (47). Classic studies by Ole Mjøs in
closed-chest dogs demonstrated that increasing the rate
of fatty acid uptake by the heart with an infusion of
heparin and triglyceride emulsion resulted in a 26% in-
crease in myocardial oxygen consumption without chang-
ing the mechanical power of the LV (309, 310). A similar
decrease in cardiac mechanical efficiency with elevated
plasma FFA concentration was observed in healthy hu-
mans (421) and pigs (232), as well as during ischemia of
moderate severity in dogs (227, 311). Furthermore, inhi-
bition of fatty acid -oxidation by 4-bromocrotonic acid
decreased MV˙O2 and improved mechanical efficiency of
the LV of the working rat heart (183); a similar response
was observed following acute administration of the fatty
acid oxidation inhibitor ranolazine in dogs with HF (53).
Korvald et al. (232) compared the relationship between
MV˙O2 and the LV pressure-volume loop over a wide range
of work loads in anesthetized pigs. Treatment with insulin
and glucose resulted in a 39% reduction in noncontractile
basal MV˙O2 [estimated from the intercept of the MV˙O2-
pressure-volume loop relationship (232)] compared with
pigs subjected to high plasma fatty acids. Importantly,
they did not observe a difference in the slope of this
relationship, suggesting that under these conditions fatty
acids did not affect excitation-contraction coupling or the
ATP requirement for contractile power.
The mechanisms for impaired mechanical efficiency
with high fatty acid oxidation are unclear. On a theoreti-
cal basis, fatty acid oxidation requires a greater rate of
oxygen consumption for a given rate of ATP synthesis
than do carbohydrates (428). The theoretical ATP-to-oxy-
gen ratio for glucose or lactate are 3.17 and 3.00, respec-
tively, while for palmitate and oleate the values are 2.80
and 2.86, respectively (209, 428). The actual values in vivo
may be much lower due to constitutive leakage of protons
across the inner mitochondrial membrane (37, 370, 371,
439). Fatty acid concentrations uncouple oxidative phos-
phorylation (decrease the P/O) and cause wasting of O2
by mitochondria (34, 348). This would require a greater
MV˙O2 for a given rate of ATP formation by oxidative
phosphorylation when fatty acids are the substrate (34,
348). These effects would alter the MV˙O2 requirement for
ATP production for both basal metabolism and for gen-
erating contractile power and relaxation (i.e., ATP hydro-
lysis to support Ca2 uptake into the sarcoplasmic retic-
ulum). In addition, high concentrations of long-chain fatty
acids can also activate sarcolemmal Ca2 channels, which
would increase the entry of extracellular Ca2 into the
cytosol and increase the rate of ATP hydrolysis required
to maintain normal cytosolic Ca2 cycling (173).
It has been proposed that fatty acids waste ATP (and
hence O2) through the extrusion of long-chain fatty acids
out of the mitochondria via uncoupling protein 3 (UCP3)
(166, 408). In this scheme high rates of intramitochondrial
fatty acyl-CoA production would result in formation of
FFA by mitochondrial thioesterase-1, which would be
transported out of the mitochondria by UCP3 and rees-
terified by FACS to long-chain fatty acyl-CoA in the cy-
tosol (a reaction that consumes two ATP) (166, 178).
Garlid and co-workers (120–123, 193, 198–201) observed
that UCP3 can translocate the FA out of the mitochon-
drial matrix; once in the intramembranous space, the FA
can associate with a proton. The resulting neutral FA
species is able to “flip-flop” back into the mitochondrial
matrix, where it relinquishes the proton. The net effect is
a leak of protons, as with classic uncoupling, but with no
net flux of fatty acids (120–123, 193, 198–201). While this
clearly occurs, it may not play a major role in the energy-
wasting effects of fatty acid observed in vivo, as many
studies show no effect of UCP3 content on the P/O in
isolated mitochondria (60, 62, 222, 408, 478). Studies in
isolated skeletal muscle mitochondria show that lipid
substrate (palmitoylcarnitine or palmitoyl-CoA) causes a
UCP3-dependent decrease in state 4 respiration with no
change in state III respiration or P/O, an effect that is not
observed with nonlipid substrates (222). In addition, skel-
etal muscle mitochondria isolated from mice lacking
UCP3 show a decreased in state 4 respiration (478) and
mice overexpressing UCP3 show an increase in state 4
respiration (60) with no effect on state 3 respiration (60,
478). Thus exposure of the myocardium to high plasma
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concentrations of FFA could waste ATP via this UCP3-
mediated futile cycle.
G. Role of Nitric Oxide in Regulation of
Myocardial Energy Substrate Metabolism
In 1989, Brune and Lapetina demonstrated that nitric
oxide (NO) can enhance ADP-ribosylation of a 37-kDa
cytosolic protein (43), later identified as GAPDH (90, 91,
313, 475), a key enzyme of the glycolytic pathway. Zhang
and Snyder documented a similar action of NO in neuro-
nal cells (517). These seminal studies on the direct effects
of NO on glucose metabolism were followed by others
that described inhibitory actions of NO on phosphofruc-
tokinase of pancreatic islets (465) and an indirect stimu-
latory action of NO on 6-phosphofructo-2-kinase in neu-
rons (4). Although the mechanisms are still poorly de-
fined, convincing evidence has been provided that NO
also plays an important role in the regulation of myocar-
dial substrate metabolism. Depre et al. (83) observed a
decreased glucose uptake in isolated hearts during 8-
bromo-cGMP infusion. They concluded that NO, via its
second messenger cGMP, probably inhibits glucose trans-
port into cardiomyocytes and that this could explain their
previous findings of a cardioprotective action of NO syn-
thase (NOS) inhibition during myocardial ischemia (84,
87), when cardiac function is highly dependent on glyco-
lytic flux. In hearts isolated from endothelial cell NOS
knockout mice, Tada et al. (447) found that basal cardiac
glucose uptake is markedly increased and can be inhib-
ited by 8-bromo-cGMP. It is possible that all of these
findings in vitro were affected by nonphysiological con-
ditions of substrate and oxygen supply. This was not the
case, however, since we found that cardiac glucose up-
take and oxidation are increased after systemic NOS in-
hibition in conscious dogs (360, 361). Conversely, under
the same experimental conditions, fatty acid uptake and
oxidation are reduced. On the other hand, we did not
observe this shift in substrate oxidation with NOS inhibi-
tion in isolated rat hearts (239). An interesting paradox is
that NO/cGMP exerts opposite effects on glucose trans-
port and metabolism in skeletal muscle (512). Additional
research is needed to elucidate the mechanisms under-
lying the regulation of myocardial substrate metabolism
by NO.
It has been suggested that the activity of cardiac NOS
during metabolic stress is regulated by a possible feed-
back mechanism involving AMPK (57). Chen et al. (57)
found that AMPK coimmunoprecipitates with cardiac
eNOS and activated it by phosphorylating Ser-1177, but
only in the presence of Ca2-calmodulin, both in tissue
homogenates and in ischemic isolated rat hearts. Because
NO is a main regulator of vascular tone and cardiac
function, these findings lead to the intriguing hypothesis
that the stimulatory effect exerted by AMPK on eNOS may
represent a link between metabolic adaptations and car-
diovascular function under conditions of stress. Li et al.
(255) also observed coprecipitation of AMPK and eNOS
and demonstrated that activation of AMPK with 5-amino-
4-imidazole-1--carboxamide ribofuranoside (AICAR) re-
sults in activation of eNOS, GLUT4 translocation and
greater glucose uptake in isolated papillary muscles.
AICAR treatment also results in increased glucose uptake
(255), which is in contrast with previous studies showing
decreased glucose uptake with NOS inhibition or 8-
bromo-cGMP (83, 84, 87, 360, 361). Additional research is
needed to elucidate the mechanisms underlying the com-
plex interactions between myocardial substrate metabo-
lism and NO.
III. REGULATION OF MYOCARDIAL
METABOLIC PHENOTYPE
Myocardial metabolic phenotype can be defined as
the substrate preference by the heart at a given metabolic
milieu (e.g., arterial concentrations of glucose, lactate,
fatty acids, insulin, catecholamines, oxygen), hemody-
namic condition (heart rate, preload, afterload, coronary
blood flow), and inotropic state. This phenotype is pri-
marily dependent on the content of the proteins (enzymes
and transporters) that facilitate flux through the meta-
bolic pathways and the structure and integrity of key
cellular organelles, such as mitochondria, that are respon-
sible for energy metabolism. To affect metabolic pheno-
type, however, it is important that the protein that is
modified exerts a key regulatory role in metabolism. Many
metabolic enzymes in a pathway are redundant or ex-
pressed in great excess and therefore do not regulate flux
through the pathway. It is therefore possible to have
dramatic changes in expression of some proteins without
much effect on substrate flux. In other words, changes in
flux cannot simply be inferred from changes in enzyme
activity or expression. Therefore, in evaluating the effects
of heart failure on myocardial substrate metabolism, it is
important to assess several aspects of the metabolic path-
way of interest, specifically: 1) the rate of flux through
metabolic pathways under physiologically relevant condi-
tions; 2) the expression, activity, and characteristics of
key regulatory proteins (e.g., Vmax, Km, allosteric modifi-
cation of an enzyme); and 3) the tissue content of regu-
latory metabolites.
There have been a variety of investigations into the
metabolic phenotype changes that occur in response to
chronic cardiac stress like cardiac hypertrophy and HF.
These studies have used a variety of methodological ap-
proaches but have mainly been aimed at the assessment
of flux through the metabolic pathway [either in vivo
using invasive (30, 31, 338, 493, 494) or noninvasive tech-
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niques, e.g., positron emission tomography (PET)] (79, 81,
237, 453, 480), or in isolated perfused hearts (24, 224, 269),
or they have sampled the myocardium to evaluate mRNA
levels using real-time quantitative polymerase chain reac-
tion (86, 356, 357, 509) or gene chip microarrays (307,
451). It is more complex to assess changes in the protein
expression, activity, and rate of turnover. Nevertheless, in
studying the effects of HF on metabolic phenotype, the
goal has been to understand the relative importance of
changes in the function of selected proteins on the flux
through various metabolic pathways, on cardiac function,
and on the progression of HF. At present, much emphasis
is placed on understanding the mechanisms that signal
changes in the expression of genes encoding proteins that
regulate substrate metabolism and, in turn, affect cardiac
function and progression in HF. However, as discussed,
care should be taken in interpreting these data without
parallel measurements of metabolic flux.
A. Control of the Expression of Metabolic
Enzymes in the Heart
Regulation of the expression of the multitude of en-
zymes and transporters involved in myocardial energy
metabolism is complex and not well understood. In HF,
recent interest has focused on altered expression of both
glycolytic and mitochondrial enzymes. In general, the
overall capacity for oxidative metabolism in a cell is
dependent on the volume density and composition of
mitochondria. However, over the last decade it has be-
come clear that mitochondrial fuel selection can be al-
tered by differential expression of enzymes of the fatty
acid oxidation pathway relative to enzymes that oxidize
pyruvate (PDH and PDK) or acetyl-CoA (e.g., citrate syn-
thase), or those in the electron transport chain. Mitochon-
dria have a circular DNA genome that encodes for the 13
subunits of the respiratory complexes I, III, IV, and V
(400). The remaining respiratory subunits and all of the
proteins required for carbon substrate metabolism are
encoded by nuclear genes. It is becoming clear that both
nuclear and mitochondrial transcription alterations are
important in the metabolic phenotype changes observed
in HF (124, 477).
An important nuclear gene transcription control that
regulates the capacity for myocardial mitochondrial fatty
acid oxidation is regulated by the ligand-activated tran-
scription factors, named peroxisome proliferator-acti-
vated receptors, or PPARs (25, 180). These transcription
factors control gene expression by first forming het-
erodimers with retinoid X receptors and then binding to
specific response elements (PPAR response elements, or
PPREs) located within promoter regions of many genes
encoding metabolic enzymes (Fig. 6). In addition, the
PPAR/RXR complex is positively regulated by the cofac-
tor PPAR coactivator-1 (PGC-1) (25, 180, 476). Cardiac
overexpression of PGC-1 increases the mRNA of numer-
ous mitochondrial genes and triggers mitochondrial bio-
genesis (181, 250, 476). Once bound to the PPRE, the
PPAR/RXR/PGC-1 complex increases the rate of tran-
scription of fatty acid oxidation genes and PDK-4 (the
inhibitory kinase of PDH) (129, 150, 172, 251). In addition,
stimulation of gene transcription is inhibited by the bind-
FIG. 6. Regulation of expression of met-
abolic genes in cardiomyocytes by stimula-
tion of the peroxisome proliferator activated
receptor  (PPAR). Note that PPAR has
similar, but less well described, effects on
gene expression (see text). ACC, acetyl-CoA
carboxylase, mCPT-I, muscle isoform of car-
nitine palmitoyltransferase-I; FABP, fatty
acid binding protein; LCAD, long-chain acyl-
CoA dehydrogenase; MCAD, medium-chain
acyl-CoA dehydrogenase; MCD, malonyl-
CoA decarboxylase; MTE1, mitochondrial
thioesterase 1; PDK4, pyruvate dehydroge-
nase kinase 4; PPRE, peroxisome prolifera-
tor activated receptor response element;
RXR, retinoid X receptor ; UCP3, uncou-
pling protein 3.
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ing of several cofactors such as COUP and SP1 (251). The
activity of PPAR/RXR heterodimers is increased by fatty
acids and eicosanoids; thus PPAR/RXR heterodimers act
as lipid sensors in the cell, resulting in a greater capacity
for fatty acid catabolism in response to a greater cell
exposure to lipid (Fig. 6) (25, 180).
There are three isoforms of PPARs: PPAR, PPAR
/, and PPAR (25, 129, 180, 251, 472). PPAR expres-
sion is high in tissues that have high rates of fatty acid
oxidation (heart, liver, brown fat, kidney) and regulates
the expression of key components of fatty acid uptake,
esterification, and oxidation by transcriptional activation
of genes encoding for key proteins in the pathway (Fig. 6).
In the heart, PPAR forms a heterodimer with RXR; the
natural activating ligand for RXR is 9-cis-retinoic acid
(25). Activation of PPAR by pharmacological ligands
(e.g., fenofibrate, clofibrate, or WY-14,643) increases the
expression of fatty acid oxidation enzymes (129, 180, 509)
and the rate of fatty acid oxidation in cardiomyocytes
(129). Consistent with these findings is the observation
that PPAR knockout mice have low expression of fatty
acid oxidation enzymes and suppressed fatty acid oxida-
tion (48). It was also recently demonstrated that PPAR
regulates the expression of UCP3 (511) and mitochondrial
thioesterase 1 (437) in the heart and thus plays a role in
regulating the extrusion of fatty acyl-CoA from the mito-
chondria (166).
PPAR [also referred to as PPAR/ (129)] is also
expressed in cardiomyocytes and stimulates the expres-
sion of proteins in the fatty acid oxidation pathway in a
manner similar to PPAR (58, 129). Gilde et al. (129)
showed that exposure of isolated neonatal rat cardiomyo-
cytes to PPAR agonists results in upregulation of the
mRNA for fatty acid oxidation enzymes and increased
fatty acid oxidation. Cheng et al. (58) recently showed
that mice with a cardiomyocyte-restricted deletion of
PPAR downregulated the expression of the mRNA and
protein for fatty acid oxidation enzymes and had reduced
myocardial oxidation of fatty acids. The mice had pro-
gressive LV dysfunction and hypertrophy, but had myo-
cardial lipid accumulation and increased mortality late in
life. These recent findings suggest that PPAR may play a
role that is similar to PPAR in the regulation of cardiac
fatty acid metabolism.
PPAR mRNA is expressed at very low levels in
cardiomyocytes, and at higher rates in a broad range of
tissues including skeletal muscle, colon, small and large
intestines, kidney, pancreas, and spleen. Although PPAR
does not appear to play a direct role regulating fatty acid
oxidation in the heart (129, 216), it can indirectly regulate
fatty acid oxidation by decreasing the fatty acid concen-
tration to which the heart is exposed. The effective insu-
lin-sensitizing agents, the thiazolidinediones, are PPAR
ligands and act to sequester fatty acids in adipocytes,
lower circulating fatty acids, and triglycerides and there-
fore reduce the exposure of the myocardium to fatty acids
(25). Thus the thiazolidinediones (“PPAR agonists”) can
decrease myocardial fatty acid oxidation in vivo by de-
creasing plasma fatty acid levels and thus myocardial
fatty acid uptake and oxidation. Furthermore, the action
of PPAR agonists on adipocytes likely reduces ligand
stimulation of the PPAR/RXR complex in cardiomyo-
cytes, and thus reduces the expression of proteins regu-
lating fatty acid uptake and oxidation in the heart.
Recent studies in isolated neonatal cardiomyocytes
suggest that the orphan nuclear receptor estrogen-related
receptor  (ERR) interacts with PGC-1 and binds to the
PPRE to increase the expression of PPAR-regulated
genes and increased fatty acid uptake, accumulation, and
oxidation (181, 182). Overexpression of ERR also re-
sulted in an increase in the mRNA for proteins that are not
regulated by PPAR, including contractile proteins and
enzymes involved in carbohydrate metabolism and mito-
chondrial respiration (182). The endogenous ligand(s) for
ERR have not been identified.
B. Cardiac Lipotoxicity
Recent evidence from animal studies demonstrates
that obesity and elevated plasma fatty acid and triglycer-
ides can result in a cardiac specific “lipotoxicity,” charac-
terized by accumulation of neutral lipids (triglycerides)
and ceramides, which are associated with increased apo-
ptosis, and contractile dysfunction (109, 301, 402, 468,
469, 501, 505, 520). For instance, Zhou et al. (520) showed
that mature obese Zucker diabetic rats develop cardiac
dilatation and reduced contractility that correspond with
elevated myocardial triglycerides, ceramide, and DNA
laddering, an index of apoptosis. Suppression of plasma
triglyceride with the PPAR agonist troglitazone lowers
myocardial triglyceride and ceramide content, which was
associated with complete prevention of DNA laddering
and loss of cardiac function. Cardiac overexpression of
FACS results in lipid accumulation, cardiac hypertrophy,
gradual development of LV dysfunction, and premature
death (59). Cardiac overexpression of human lipoprotein
lipase with a glycosylphosphatidylinositol anchoring se-
quence that localizes the enzyme to the surface of cardi-
omyocytes causes LV chamber enlargement and impaired
contractile function compared with wild-type mice (501).
The mechanism for lipid-induced cardiac remodeling and
dysfunction in this model is unclear but could be due to
apoptotic cell loss (162, 260, 333, 425, 520) and/or a de-
crease in cardiac mechanical efficiency with very high
rates of fatty acid oxidation and impaired carbohydrate
oxidation (227, 232, 309, 310, 421).
The toxic effects of lipid accumulation in the heart
can be demonstrated in small animal models; however,
the clinical significance of these findings is not yet clear in
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type 2 diabetes, obesity, and HF. Epidemiological studies
show that obese people have a decrease in life expectancy
and greater mortality from cardiovascular disease (113,
174) and a greater risk for developing HF (218). However,
once a patient is diagnosed with HF, there is a paradox-
ical reduction in the rate of mortality in obese compared
with lean patients (80, 171, 247, 248). These observations
are complicated by the fact that cachexia is a positive
predictor of mortality in HF, and weight loss is strongly
associated with poor outcome (7, 80). The clinical com-
plexities of the HF and obesity, and the paucity of data,
make it impossible to draw conclusions at this point
regarding mechanistic interactions between the two syn-
dromes.
C. Regulation of Phenotype Switch from Fetal to
Adult State: Implications for Heart Failure
One of the hallmarks of HF is a reexpression of fetal
forms of genes expressing contractile proteins, specifically
myosin (411). A similar reexpression of some fetal metabolic
genes has been noted in HF; however, there is not a clear
recapitulation of the fetal metabolic phenotype (see discus-
sion below) (356, 362, 374, 388, 389). Nonetheless, much can
be learned about the regulation of metabolic phenotype by
studying the rapid transformation in enzyme pathways and
substrate use that occurs during the transition from the fetal
to neonatal state. During the fetal stages of the developing
mammalian heart, glucose is the primary energy substrate
for energy transduction, while rates of fatty acid oxidation
are very low (130). In the fetal and immediate newborn
period, the heart is very reliant on glycolysis as a source of
energy (110, 272) due both to higher activities of the en-
zymes in the glycolytic pathway (110, 169, 282, 372) and
altered pathway regulation (272, 460) in fetal hearts. Direct
measurements of glycolysis in perfused rabbit hearts dem-
onstrate that in the immediate newborn period, 44% of the
ATP production is derived from glycolysis (274); however,
within days of birth glycolysis decreases and provides only
7% of ATP production, values similar to those seen in the
adult rabbit heart (273, 274). Even though glycolysis is high
in the fetal and newborn heart, these hearts still have a
considerable mitochondrial oxidative capacity (273, 274,
482, 483). Fetal hearts readily extract (110–112) and oxidize
lactate (489), and because circulating lactate levels are very
high in the fetus (130), lactate oxidation accounts for the
majority of myocardial oxygen consumption (110, 111).
While glycolytic rates are high in the immediate newborn
period, glucose oxidation is very low and is not a major
source of ATP production (274, 275). The capacity to oxidize
glucose increases as the heart matures (192, 272, 273).
In the fetal and newborn heart, fatty acid oxidation
rates are low and provide only a small proportion of
overall ATP production (130, 132, 273, 274). In the imme-
diate newborn period, 20% of the heart’s ATP require-
ments are met by the oxidation of fatty acids (274). How-
ever, after birth, there is a dramatic 10-fold increase in
fatty acid oxidation, which is accompanied by a parallel
decrease in glycolytic rates (192, 274). This is opposite to
the switch towards reduced fatty acid oxidation and in-
creased glucose oxidation observed in some forms of
severe HF. Interestingly, if the newborn heart is subjected
to a volume overload hypertrophy, the expression and
activity of key enzymes controlling fatty acid oxidation
remain in the “fetal state” (208).
A number of key enzymes involved in fatty acid oxi-
dation are altered in the transitions from fetal to adult
metabolism. In the fetal heart there is a greater proportion
of CPT-I relative to CPT-I, a phenomenon similar to
what is observed in cardiac hypertrophy (41, 304, 461,
497). However, one of the most dramatic differences in
fatty acid oxidation control in the newborn period is the
levels of malonyl-CoA, and the control of malonyl-CoA
levels (275, 282). In the immediate newborn period, mal-
onyl-CoA content in the heart is very high, but then rap-
idly decreases within days of birth (92, 275, 282). This
dramatic drop in malonyl-CoA is an important contributor
to the maturation of fatty acid oxidation following birth
(275) and is due to both decreased synthesis by ACC and
increased degradation by MCD (92, 275). The decrease in
ACC activity with maturation is due to an increase in
AMPK activity following birth (92), which phosphorylates
and inhibits ACC activity (275). An increase in AMPK
activity has also been observed with cardiac hypertrophy
in the rat, illustrating that there is not a simple switch to
fetal metabolic regulation in response to chronic cardiac
stress (462). The increase in MCD activity in the newborn
period is primarily due to an increase in MCD expression
(92), which may be due to activation of PPAR, a known
transcriptional regulator of MCD (48, 508). The role of
PPAR in HF is discussed below.
D. Effects of Aging on Substrate Metabolism
It is important to consider that the incidence of HF is
directly related to age (33) and that the progression from
adulthood to senescence affects cardiac contractile prop-
erties and LV chamber size (241, 242, 422), myocardial
flow reserve (471) and cardiac mitochondria function
(104, 147, 253, 276), and affects myocardial substrate
metabolism independent of HF. Recent studies using PET
show that with aging (69 vs. 29 years of age), humans
have a decrease in myocardial fatty acid uptake and oxi-
dation, with no change in glucose uptake under resting
conditions (211). However, when MV˙O2 is increased by an
infusion of dobutamine, there is a similar increase in
myocardial fatty acid uptake in both young and old sub-
jects, and an increase in glucose uptake in the young
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subject but not in the old subjects. This is in contrast to
studies in perfused rat hearts, where there was no differ-
ence between 6 and 24 mo in palmitate oxidation for a
given MV˙O2 at either low or high work loads (3). Old rats
have a decrease in myocardial GLUT4 mRNA and protein
content that is not affected by exercise training by tread-
mill running (144). McMillin et al. (303) observed a de-
crease palmitoylcarnitine oxidation, CPT-I activity, and
carnitine exchange in isolated mitochondria from old rats
compared with adult animals. In addition, old animals did
not exhibit fatty acid suppression of glucose oxidation
that was evident in the adult rat heart, consistent with the
concept of an aging defect in long-chain fatty acid oxida-
tion (303). Iemitsu et al. (186) found a decrease in mRNA
and protein expression for PPAR in 23- compared with
4-mo-old rats and that this decrease was prevented by
swim training from 21 to 23 mo. Aging resulted in a
decrease in the activity of cytochrome oxidase, citrate
synthase, and 3-hydroxylacyl-CoA dehydrogenase, which
was also prevented by 2 mo of swim training (186). Most
animal studies investigating the pathophysiology of HF
are performed in juvenile or young adult animals, and
thus the effects of age are not present, suggesting that one
should be cautious in interpreting such data.
IV. METABOLIC PHENOTYPE
IN HEART FAILURE
A. Considerations Regarding the Etiology
of Heart Failure
The etiology of HF can be divided into two broad
categories: those patients with a history of myocardial
ischemia/coronary artery disease (approximately two-
thirds of all patients) and those without a history of
coronary disease (“idiopathic cardiomyopathy”) (215).
The early stages of HF are often clinically asymptomatic
due to physiological compensatory mechanisms (e.g., ac-
tivation of the renin-angiotensin system, greater sympa-
thetic nervous system activity, and development of cardio-
myocyte hypertrophy); however, these same mechanisms
also contribute to the progression of HF by precipitating
ventricular remodeling (increased LV chamber volume,
wall thinning, and myocardial fibrosis). It is important to
note that inborn errors in mitochondrial metabolism and
the electron transport chain can result in cardiomyopathy
and present as clinical HF (49, 156, 217, 285); however,
this area is outside the scope of the present review.
Due to the difficulties in obtaining myocardial tissue
samples and assessing substrate flux in humans, little is
known about myocardial substrate metabolism in HF pa-
tients. Furthermore, analysis of data from patients is com-
plicated by the diverse etiology of the HF syndrome, the
numerous pharmacotherapies used to treat these pa-
tients, the presence of complicating disorders (diabetes,
insulin resistance, obesity), and the clinical stage. At
present, there are few measurements of myocardial sub-
strate metabolism in HF patients. Several studies have
assessed levels of mRNA and protein expression in myo-
cardium from hearts explanted from HF patients under-
going transplantation. However, these studies are com-
promised by the lack of a proper “normal” control group
(the HF samples are rapidly obtained, while the control
tissue is generally obtained from donor hearts that were
unacceptable for transplantation and thus are usually on
ice from several hours before processing). Despite these
limitations, there is clear agreement between animal and
human studies on many of the effects of HF on changes in
the expression of key metabolic enzymes (see below).
The greatest impediment to understanding myocar-
dial metabolism in HF is the limitations of existing animal
models of HF (10, 317, 347, 386). Human HF of ischemic
origin usually develops slowly following a myocardial
infarction, affecting areas of the ventricle remote from the
infarcted regions that have normal myocardial blood flow.
While transient HF can occur during the acute phase of a
myocardial infarction or with unstable angina, chronic HF
slowly develops after establishment of the infarct, with
evolution of LV remodeling and adverse changes in both
the infarcted and the noninfarcted regions. Several animal
models have been developed to mimic this condition,
specifically the rat infarct model (263, 342, 343), the ca-
nine direct-current shock model (299), and the pig infarct
model (262). Like in humans, in these models infarction
does not always result in true HF (i.e., decreased LV
systolic function, chamber dilation, or elevated LV end-
diastolic pressure), although a predictable number of an-
imals progress to a state similar to human HF. A particu-
larly robust and well-characterized canine model of HF
has been developed by Sabbah et al. (386), where HF is
produced by repeated bouts of ischemic injury induced by
microembolizations caused by intracoronary injections of
90-m-diameter microspheres 4–7 times 1 wk apart,
which generates diffuse infarcts and progressive LV dys-
function, chamber dilation, and HF (384, 418).
Clinically, HF can develop in the absence of coronary
artery disease in patients with a history of LV hypertrophy
due to hypertension or aortic stenosis, though unlike HF
in patients with a history of ischemic heart disease, LV
chamber dilation develops relatively late in hypertensive
patients who progress to HF (215). Animal models of LV
hypertrophy have been developed using chronic aortic
constrictions in rats, dogs, and pigs (504, 516). There are
numerous studies on the effects of LV hypertrophy in
rodents on myocardial substrate metabolism in the ab-
sence of HF (16, 251, 291, 396, 516, 518); however, there
are few studies where the animals actually progressed
from concentric LV hypertrophy to overt HF (e.g., de-
creased cardiac output, LV ejection fraction, and increase
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LV end-diastolic pressure). In dogs and pigs subjected to
aortic constriction, HF develops after 6–12 mo in40% of
the animals, whereas the remaining animals hypertrophy
but do not progress to failure (167, 504).
Another widely used model that does not involve
myocardial ischemic injury is the rapid pacing-induced
model in dogs, where the heart rate is increased to 220
beats/min, resulting in decompensated end-stage failure
after 4–6 wk of pacing. This model is highly reproducible
and has also been produced in pigs, sheep, and rabbits
(10, 317, 347). The mechanisms that precipitate HF in the
model are related to neurohormonal activation secondary
to poor cardiac function, presumably due to poor dia-
stolic filling and increased metabolic stress and decreased
phosphorylation potential (314, 420).
B. Electron Transport Chain and Oxidative
Phosphorylation Defects in Heart Failure
The focus of this review is on the metabolism of
carbon substrates in HF. However, the ultimate fate of the
reducing equivalents generated from intermediary metab-
olism is the electron transport chain (ETC) and oxidative
phosphorylation, making it important to briefly address
this topic (Fig. 7) [the reader is referred to several recent
reviews that more specifically address mitochondrial and
ETC defects in HF (49, 98, 253, 287, 477)]. In addition, HF
generates defects in the transfer of the energy from mi-
tochondrial ATP to the site of ATP hydrolysis and the
function of the creatine phosphate system (97–99, 190,
257, 322–324, 463, 477); however, this topic is outside the
scope of this review.
Studies in patients and animal models show that
there is a decrease in tissue ATP content, a rise in ADP,
and a fall in the phosphorylation potential (21, 22, 189,
257, 298, 314, 322–324, 420, 463, 470), thus impairing the
kinetics for ATP utilization for cell contraction (myosin
ATPase) and relaxation (sarcoplasmic reticulum Ca2-
ATPase). In addition, HF impairs the capacity for the
creatine kinase system to transfer mitochondrial ATP to
the myofibril (88, 97, 98, 257, 463, 477, 504). An impaired
ETC could also affect the mitochondrial and cytosolic
redox state (NADH/NAD) and the concentrations of
ATP, ADP, and Pi, which could influence the rate of flux
through key metabolic enzymes such as PDH or phospho-
fructokinase.
Mitochondria in the failing heart are characterized by
a greater occurrence of membrane disruption and matrix
depletion (383, 403, 417, 419), a lower capacity for respi-
ration with a variety of substrates (136, 170, 334, 383,
397–399, 419), defects in complexes of the ETC (44, 49,
196, 286, 287, 298, 349, 404), and a decreased capacity for
oxidative phosphorylation (49, 253, 262, 286, 349). In rats
with infarct-induced HF, there is a decrease in myocardial
ATP and creatine phosphate and in ADP stimulated res-
piration in isolated permeabilized myocyte bundles with
glutamate and malate as substrates at 12 wk after coro-
nary ligation (397–399). Myocardial homogenates from
cardiomyopathic Syrian hamster have a decreased ability
to oxidize fatty acids (19, 205), which was subsequently
shown by Hoppel et al. (170) to reflect a generalized
defect in oxidative metabolism that is not specific for fatty
acids. This defect in oxidative phosphorylation was found
in interfibrillar mitochondria, and not in subsarcolemmal
mitochondria (170). To our knowledge, this is the only
study to investigate the effects of HF on select popula-
tions of cardiac mitochondria (253).
Studies in patients and animals with HF show a re-
duced activity of several ETC complexes. Jarreta and
co-workers (49, 196) measured the activity of complexes
I-IV in myocardial biopsies from HF patients. They ob-
served that the activity of complex III was reduced by 35%
with no changes in the other complexes in patients with
either idiopathic dilated cardiomyopathy or a history of
ischemic heart disease compared with donor hearts with
normal cardiac function. The only genetic defects they
found were neutral polymorphisms in the cytochrome b
gene, strongly suggesting that the decreased activity in
the respiratory chain complex III activity was not due to
expression of an abnormal gene (196). This observation is
FIG. 7. The electron transport
chain. Studies in heart failure (HF) pa-
tients show conflicting results, with re-
duced activity of either complex I (404),
complex III (49, 196), or complexes III
and IV (44). Conflicting results are also
reported in the canine rapid pacing
model of HF, with defects observed in
either complex I activity (184) or in com-
plexes III and V (286). CAC, citric acid
cycle; FAO, fatty acid -oxidation;
PDH, pyruvate dehydrogense.
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further supported by the fact that patients with a congen-
ital complex III defect do not present with cardiomyopa-
thy (316). Depressed complex III activity could not be
attributed to mitochondrial DNA damage or depressed
mitochondrial gene expression (196). Buchwald et al. (44)
measured the activity of the ETC complexes in isolated
mitochondrial particles from transplant recipients with
dilated cardiomyopathy (DCM) and from unused donor
hearts. Cytochrome c content and the activity of com-
plexes III and IV were decreased by 21, 24, and 28%
compared with donor hearts, with no differences in the
activities of complexes II and V. On the other hand,
similar measurements of respiratory complex activities in
HF patients by Scheubel et al. (404) showed a 28% de-
crease in complex I activity compared with donor hearts,
but no changes in complexes II-IV or of the CAC enzyme
citrate synthase.
Defects in the ETC have also been identified in the
canine rapid pacing model of HF. Marin-Garcia et al. (286)
showed that in severe end-stage decompensated pacing-
induced HF (LV end-diastolic pressure of 38 mmHg),
there was no decrease in the activities of complexes I, II,
or IV, but a highly significant decrease in the activities of
complexes III (81% reduction) and V (70% reduction),
with no change in the activity of citrate synthase. They
also observed a similar reduction in the activities of these
enzymes, although to a lesser extent, in skeletal muscle.
The defects in ETC complexes were correlated to plasma
concentration of tumor necrosis factor- (286), and treat-
ment of dogs with etanercept, a soluble tumor necrosis
factor receptor fusion protein, partially prevents the de-
fect, suggesting the possibility that tumor necrosis fac-
tor- somehow regulates ETC complexes III and IV (312).
In contrast, using the same pacing-induced canine model
of HF, Ide et al. (184) reported a 50% decrease in complex
I activity in cardiac submitochondrial particles, which
was associated with greater production of reactive oxy-
gen species.
Regardless of such differences among studies, these
findings are consistent with the concept that in HF there
is a major lesion in oxidative metabolism at the level of
the ETC. On the other hand, there is a large disparity
among the clinical and experimental studies regarding the
sites of the lesions in the respiratory chain. It is also
unclear if 1) these effects are isolated to a subpopulation
of cardiomyocytes, or if they occur uniformly throughout
all cells, or 2) they are localized to either subsarcolemmal
or intrafibrillar populations of mitochondria. In addition,
the consequences of these lesions on cardiac metabolism,
oxidative damage, and contractile function are not clear.
One possibility is that impairment in the ETC reduces the
in vivo capacity for myocardial ATP generation and thus
limits cardiac contractile function during high work
states, such as exercise or acute adrenergic stress. Niko-
laidis et al. (328) recently observed a reduced MV˙O2 re-
sponse to increased cardiac power in dogs with pacing-
induced HF that was due to a limitation in oxygen extrac-
tion, but not in myocardial blood flow. These finding are
consistent with the concept of impaired mitochondrial
respiratory capacity in HF, resulting in reduced ability to
generate ATP in response to increased demand for car-
diac power.
Recent studies demonstrate that downregulation of
fatty acid oxidation enzymes can be triggered by a defect in
the ETC in the mouse heart (149). Hansson et al. (149)
knocked out mitochondrial transcription factor A and ob-
served a progressive decline in ETC activities and mitochon-
drial ATP production. The downregulation of enzymes of
fatty acid oxidation occurred early in the development of
mitochondrial dysfunction and was accompanied by an up-
regulation of hexokinase with no change in other glycolytic
enzymes. The mechanisms that link impaired respiratory
chain function to changes in the expression of metabolic
genes are unclear. Nevertheless, these findings suggest the
possibility that the metabolic switch in HF could be second-
ary to impaired ETC function.
C. Substrate Metabolism in Heart Failure
1. Results from HF patients
While numerous studies in patients and animal mod-
els show that HF reduces the capacity to transduce the
energy from foodstuffs into ATP, less is known about the
effects of HF on myocardial substrate metabolism and
fuel selection. There are few measurements of myocardial
substrate oxidation in HF patients, and the results are
somewhat conflicting. In general, the data support the
concept that in the early stages of HF there is a normal (or
slightly elevated) rate of fatty acid oxidation, and in ad-
vanced or end-stage HF there is downregulation of fatty
acid oxidation. Paolisso et al. (338) found increased ex-
traction and uptake of plasma FFA and decreased glucose
uptake in congestive HF patients [n 10; New York Heart
Association (NYHA) classes II and III] compared with
age-matched healthy individuals. In addition, the rate of
myocardial lipid oxidation, as estimated from the
transmyocardial respiratory quotient, increased by 50% in
HF patients. In these patients there was a corresponding
60% decrease in cardiac carbohydrate oxidation com-
pared with healthy controls. It should be noted that these
indirect measurements of substrate oxidation do not dif-
ferentiate between lactate, glucose, or glycogen oxida-
tion. HF patients had increased plasma norepinephrine
(5.2  0.2 vs. 1.4  0.3 pmol/ml) which corresponded to
increased plasma FFA concentrations (1.0  0.1 vs. 0.66 
0.08 mM, presumably due to greater -adrenergic stimu-
lation). However, the HF patients also had significantly
higher plasma insulin levels, which would likely stimulate
glucose uptake and oxidation by the heart. The alterna-
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tions in plasma substrate and norepinephrine concentra-
tions make if difficult to separate HF-induced changes in
myocardial metabolic pathways from changes in the met-
abolic milieu.
Using PET, Taylor et al. (453) found greater myocar-
dial uptake of a radiolabeled fatty acid analog and less
radiolabeled deoxyglucose uptake in class III HF patients
compared with healthy subjects. On the other hand, pa-
tients with idiopathic dilated cardiomyopathy appear to
have greater myocardial glucose uptake and less fatty
acid uptake compared with normal people. Yazaki et al.
(503) found a reduced retention of the radiolabeled fatty
acid analog 123I-beta-methyl-iodophenylpentadecanoic
acid (BMIPP) in circumscribed cardiac regions of patients
with severe idiopathic dilated cardiomyopathy, consistent
with impaired fatty acid utilization; however, the kinetics
of BMIPP are complex and not validated in failing myo-
cardium (228, 234, 363). A recent PET study by Da´vila-
Roma´n et al. (79) showed decreased fatty acid utilization
and increased myocardial glucose metabolism in patients
with idiopathic dilated cardiomyopathy. It is important to
note that with PET one can estimate glucose uptake from
the accumulation of 18F-deoxyglucose 6-phosphate in the
tissue during infusion of 18F-deoxyglucose tracer, or from
estimations derived from the decay in tissue 11C content
following injection of [11C]glucose; however, it is not
possible to directly measure the rate of glucose oxidation,
as done with invasive studies using [14C]glucose and myo-
cardial production of 14CO2 (492, 493). The discrepancy
among these clinical investigations may be attributable to
the severity of HF, supporting the idea that in the early
stages of HF there is a normal (or slightly elevated) rate of
fatty acid oxidation, with a dramatic downregulation of
fatty acid oxidation in advanced or end-stage HF.
2. Results from animal models of HF
Studies in the canine rapid pacing model of heart
failure by Recchia et al. (359) support the concept that
there is relatively normal myocardial substrate metabo-
lism in the early and middle stages of the development of
HF, but a sharp switch away from fatty acid towards
carbohydrate oxidation in end-stage HF (e.g., LV end-
diastolic pressure 25 mmHg). The substrate switch was
evidenced by a sharp rise in glucose uptake and a fall in
fatty acid uptake that coincided with a steep elevation in
LV end-diastolic pressure and cardiac decompensation,
all occurring during the last week of pacing. Further
support for this late switch comes from the transmyocar-
dial respiratory quotient (an estimate of substrate oxida-
tion from CO2 production and MV˙O2, with 0.7 reflecting
100% fat oxidation, and 1.0 100% carbohydrate oxidation),
which did not change significantly from the prepacing
value (0.73  0.06) at 3 wk of pacing (0.80  0.04), but
increased sharply with the onset of decompensation
(0.87  0.09, 0.96  0.08, and 1.02  0.06 at 24, 27, and 29
days of pacing). Nikolaidis et al. (329) observed a similar
fall in fatty acid uptake in end-stage HF in this model
despite a rise in plasma fatty acid concentration, but also
found decreases in glucose and lactate uptake despite no
change in MV˙O2. Studies using isotopic tracers to directly
measure substrate oxidation showed a significant in-
crease in glucose oxidation and decrease in fatty acid
oxidation in end-stage pacing-induced failure compared
with normal dogs (252, 332).
Interestingly, the metabolic changes in canine pacing-
induced HF are paralleled by a fall in cardiac production of
NO metabolites. Whether reduced NO synthesis and a
switch in substrate metabolism, in the failing heart, are
linked by a cause-effect relationship is presently unknown.
Convincing evidence indicates that NO exerts a direct action
on cardiac substrate utilization (83, 84, 358, 360, 361, 447),
but only one of those studies (447) determined the effects of
permanent reduction in NO synthesis in hearts isolated from
endothelial cell NOS knock-out mice, while the others tested
short-term effects (see sect. IIG). Molecular alterations in the
failing heart, including downregulation of metabolic en-
zymes (see sect. IV) and of NOS (423), occur over long
periods of time. Ideally, the relationship between lack of
cardiac NO and substrate selection should be tested by
reestablishing a normal NO production selectively in the
heart and during the progression of HF, a difficult task to
perform with the pharmacological tools presently available.
A further element of complexity is that the lack of NO in the
failing heart might 1) lead to excessive mitochondrial O2
consumption (498) and 2) contribute to coronary microcir-
culatory dysfunction (464), therefore causing subliminal
myocardial ischemia in the absence of coronary macrovas-
cular disease, resulting in metabolic adaptations. In fact, as
mentioned in section IVD, pacing-induced HF, similar to
human dilated cardiomyopathy, is characterized by regional
myocardial perfusion abnormalities, detectable only with
careful assessment of regional flow distribution (154, 321).
Studies in early-stage HF in the canine microemboli-
zation model suggest that the changes in substrate use are
a late-stage phenomenon. Chandler et al. (52) measured
myocardial substrate oxidation in dogs with well-compen-
sated microembolization-induced HF using isotopic trac-
ers and found no differences in myocardial glucose, lac-
tate, or fatty acid metabolism compared with normal
dogs. These results support the concept that there is not
a decrease in fatty acid oxidation early in HF and that the
dramatic downregulation of fatty acid oxidation enzymes
and the switch to carbohydrate metabolism occurs only in
more severe or decompensated HF.
Studies in rats 8 wk after myocardial infarction
showed an elevated LV end-diastolic pressure (12 vs. 3
mmHg) and decreased developed pressure (69 vs. 78
mmHg compared with sham rats in vivo) (362). When
hearts were isolated and perfused with erythrocyte con-
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taining buffer, there was no difference in MV˙O2 between
groups; however, there was an 84% increase in glucose
oxidation with no significant change in palmitate oxida-
tion (362). These results suggest that early in the devel-
opment of HF in this model there is activation of glucose
metabolism but not a reduction in exogenous fatty acid
oxidation.
D. Alterations in Expression and Function
of Metabolic Proteins in Heart Failure
Studies describing the expression of metabolic en-
zymes in HF have primarily focused on advanced end-
stage failure and have provided consistent evidence for a
downregulation of myocardial fatty acid oxidation en-
zymes, which is consistent with the switch in substrate
metabolism away from fatty acid oxidation toward
greater glucose oxidation. Sack et al. (389) showed that
explanted hearts from transplant recipients had a dra-
matic downregulation of the enzymes of the fatty acid
oxidation pathway compared with unused donor hearts.
The failed hearts had significantly reduced mRNA for the
fatty acid oxidation enzymes long-chain acyl-CoA dehy-
drogenase (LCAD) and medium-chain acyl-CoA dehydro-
genase (MCAD), as well as protein levels of MCAD, with
no downregulation of the mRNA for the glycolytic enzyme
GAPDH. Karbowska et al. (210) found a 54% reduction in
PPAR protein level in ventricular biopsies from five
patients with compensated end-stage HF compared with
control donor hearts. This suggests that the downregula-
tion of the mRNA, protein expression, and activity of
PPAR regulated genes in end-stage HF is due to less
PPAR/RXR heterodimer activity. The expression of
RXR has not been reported in HF patients.
Studies in dogs with end-stage pacing-induced HF
found a similar downregulation of enzymes involved in
fatty acid oxidation; there was a 40% reduction in the
activity and expression of MCAD and in the activity of
CPT-I, which correlated with a 40% decrease in the rate of
fatty acid oxidation and a 155% increase in the rate of
glucose oxidation measured in vivo (252, 332). Surpris-
ingly, MCAD downregulation was not paralleled by re-
duced expression of PPAR, the nuclear receptor that
controls the expression of many key enzymes of the fatty
acid oxidative pathway (Fig. 6) (332). On the other hand,
consistent with impaired fatty acid oxidation, we found a
reduced availability of RXR, the obligate cofactor of
PPAR, which significantly correlated with MCAD ex-
pression and activity. Based on previous findings in vitro
(96), we hypothesized that RXR downregulation was due
to sustained hypoxia in the paced ventricle consequent to
supply/demand mismatch, even if we could not detect
significant changes in mean coronary blood flow and in
the rate of nonoxidative glycolysis. This hypothesis is
supported by the finding that pacing-induced HF is char-
acterized by a reduced subendocardial blood flow, espe-
cially in the LV free wall, when the pacemaker is activated
(154). Similar regional myocardial perfusion abnormali-
ties have been observed with PET in patients with idio-
pathic dilated cardiomyopathy (320, 321).
Measurements of the mRNA expression in myocar-
dium from dogs with end-stage pacing-induced HF sug-
gest that not only the mRNA levels of key enzymes of the
fatty acid oxidation pathway are downregulated, but also
GLUT-1, GLUT-4, GAPDH, PDH (E2 subunit), and PDK-4
were reduced in failing hearts compared with normal
myocardium (252, 356). This suggests that the failing
heart represses the expression of all metabolic enzymes,
rather than selectively suppressing fatty acid oxidation
enzyme and potentiating the carbohydrate pathway.
Studies in less advanced HF suggest that the change
in the expression of metabolic genes is a late-stage phe-
nomenon. Chandler et al. (52) analyzed the myocardium
from dogs with well-compensated microembolization-in-
duced HF. Mitochondria were isolated for the measure-
ment of CPT-I activity and the ability of malonyl-CoA to
inhibit CPT-I activity. As discussed above, the heart ex-
presses two isoforms of CPT-I: liver (CPT-I) and heart
(CPT-I), with CPT-I not as sensitive to malonyl-CoA
inhibition as CPT-I (223, 300, 302). This has potential
significance in HF since Depre et al. (86) showed that in
human end-stage HF and in cardiac hypertrophy in the rat
heart there is a significant reduction in the mRNA for
CPT-I, but no change in the mRNA for CPT-I. This
could translate into predominance of the liver isoform in
the failing heart and loss of malonyl-CoA sensitivity (357).
However, we did not observe any difference in the max-
imal activity of CPT-I between groups, or in the sensitivity
of CPT-I to malonyl-CoA inhibition in isolated mitochon-
dria (52, 337), which suggests there was not a relative
switch from the muscle form of CPT-I to the malony-CoA
insensitive liver form. We did, however, observe a 22%
decrease in the myocardial content of malonyl-CoA in HF,
suggesting less in vivo inhibition of CPT-I activity (52). In
addition, the total activity and the activation state of PDH,
the key enzyme regulating myocardial pyruvate oxidation
(and hence glucose and lactate oxidation), was not af-
fected by HF. These data further support the concept that
in the early stages of HF the myocardium primarily relies
on fatty acid as an oxidative substrate, and that there is
not yet a switch to greater glucose oxidation and less fatty
acid oxidation.
Similar to our observations in dogs with HF, Martin
et al. (289) found that the activity of CPT-I was not
different between myocardial biopsies obtained from HF
patients undergoing transplantation compared with non-
failing donor hearts. However, they did find that the ac-
tivity of CPT-II was significantly reduced. Consistent with
this observation, the myocardial content of long-chain
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acylcarnitine was increased over fourfold, and the free
carnitine content was reduced by one-half in the HF pa-
tients. This study did not measure mitochondrial volume
density or the activity of marker enzymes (e.g., citrate
synthase), so it is unclear if the HF patients had a general
reduction in mitochondrial density.
Studies in the rat infarct model of HF found that 20
wk after coronary artery ligation there is a decrease in the
mRNA expression of selected fatty acid oxidation en-
zymes (fatty acid binding protein, MCAD, and very-long-
chain acyl-CoA dehydrogenase) with no change in CPT-I
or long-chain acyl-CoA dehydrogenase (362, 374). HF de-
velops in this model (e.g., increase in LV end-diastolic
volume and decrease in LVEF) at 12 wk after infarction
(263, 342, 343, 362, 374). There was also decreased protein
expression for MCAD (362, 374), suggesting a response
similar to patients in end-stage HF (20, 388, 389) or dogs
with decompensated pacing-induced HF (332, 359). Ie-
mitsu et al. (186) found approximately an 80% reduction
in the mRNA expression of PPAR and of the fatty acid
oxidation enzymes hydroxyacyl-CoA dehydrogense and
CPT-1 6 mo after infarction in the rat; however, protein
expression or enzyme activities were not reported.
Recent studies by Miyamoto et al. (308) in a rabbit
model of volume overload hypertrophic HF induced by a
carotid-jugular shunt found that after 6 wk there was no
downregulation of PPAR protein expression, or in the
expression of enzymes fatty acids -oxidation (308). Vol-
ume overload resulted in eccentric hypertrophy, as doc-
umented by an increase in LV end-diastolic dimension
without an increase in anterior or posterior wall thick-
ness. The myocardial uptake of the fatty acid analog
125I-iodophenyl 9-methylpentadecanoic acid was in-
creased in the volume-loaded animals, suggestive of a
greater fatty acid uptake and oxidation. Thus, in the early
stages of cardiac failure in this model, there is no down-
regulation of the fatty acid oxidation pathway, but rather
evidence for enhanced fatty acid oxidation without up-
regulation of the pathway (308).
There is little evidence for upregulation of the pro-
teins involved in the carbohydrate utilization pathway
(glucose transporters, glycolytic enzymes, or the PDH
complex) in HF. Paradoxically, there is a decrease in
glycolytic enzyme activity and expression despite in-
creased glycolysis in severe rapid pacing HF in dogs (97,
252) and in patients with either hypertrophic or dilated
cardiomyopathy (206). Studies in the rat infarct model of
HF found an increased protein expression of GLUT-1 and
downregulation of GLUT-4 compared with sham hearts
(374). We recently observed that at end-stage pacing-
induced HF in dogs, there is downregulation of mRNA for
GLUT-1, GLUT-4, and GAPDH, with no change in the
GLUT-1 and GLUT-4 protein content in the sarcolemmal
membrane, but a decrease in the protein expression and
activity of GAPDH (252). Paradoxically, there was an
increase in glucose uptake and oxidation despite down-
regulation of the pathway (252, 332). Studies in Syrian
hamsters found reduced activity of PDH in two cardio-
myopathic strains (reduction of 68–84% compared with
normal hearts) (89). When the hearts were perfused with
5 mM dichloroacetate (DCA) to inhibit PDK and convert
the enzyme to the dephosphorylated active form, there
was an increase in PDH activity and a significant increase
in systolic function of the heart, but the maximal activity
of PDH was still significantly less in cardiomyopathic
animals (32 and 38% reduction from values obtained from
normal hamsters). These results suggest that in this
model of HF there is less total PDH enzyme present and
greater phosphorylation inhibition that contributes to
contractile dysfunction. We recently observed greater
protein expression of PDK4 and less PDH E2 subunit, and
no change in PDH activity in dogs with end stage pacing-
induced HF compared with normal dogs, yet the rate of
glucose oxidation was elevated by 2.5-fold (252). Taken
together, these results suggest that any increase in glyco-
lytic flux and glucose oxidation with HF is due to alter-
ations in pathway regulation that are secondary to sup-
pression of fatty acid oxidation, and are not due to up-
regulation of proteins involved in glucose uptake,
glycolysis, or pyruvate oxidation.
Little is known about the effect of HF on myocardial
lactate metabolism. Recent studies in the rat infarct
model of HF demonstrated upregulation of the lactate
transporter MCT-1 that corresponded to an increase in the
Vmax for lactate uptake in isolated cardiomyocytes (202).
A similar increase in MCT-1 expression and myocardial
lactate transport was observed in rats with HF caused by
chronic volume overload induced by an arterial-venous
fistula (11). The effects of HF on MCT-1 expression have
not been reported in large animal HF models or patients,
nor have the effects of HF on myocardial lactate uptake
been assessed under conditions of cardiac stress or ele-
vated arterial lactate concentrations.
V. THERAPEUTIC POTENTIAL
FOR MANIPULATION OF
SUBSTRATE METABOLISM
A. Short-Term Metabolic Therapy to Optimize
Cardiac Function
On the basis of our previous discussion, increasing
the flux through PDH may improve myocardial contractile
function in HF. While this effect might not be effective in
advanced end-stage HF, where the metabolic substrate
preference has already switched to reduced fatty acid
oxidation and accelerated glucose oxidation (252, 332,
359, 389, 428), it could be effective in the earlier stages of
HF, when substrate oxidation is relatively normal (52,
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338). In support of this, Bersin and co-workers (27, 28)
observed improved contractile function in ten HF patients
(NYHA classes III and IV) treated with intravenous DCA
to inhibit PDH kinase, activate PDH, and increase pyru-
vate oxidation. DCA was infused at 1.67 mg · kg1 · min1
for 30 min, and cardiovascular measurements made dur-
ing the treatment period were compared with values ob-
tained immediately before infusion. Myocardial lactate
uptake increased during DCA infusion despite a signifi-
cant fall in arterial lactate concentration. Consistent with
a stimulation of PDH, during treatment with DCA there
was a significant increase in stroke volume and stroke
work, and an increase in LV mechanical efficiency from
15.2 to 20.6%. Although rates of glucose or FFA uptake
and oxidation were not measured, these results suggest
that DCA increases pyruvate oxidation and mechanical
efficiency by switching the heart towards the more effi-
cient fuel. However, one should use caution in interpret-
ing these results because of the lack of a vehicle-treated
control group. To establish the mechanism of action of
DCA in improving ventricular function in HF patients, it is
important to show that DCA increases the rates of glucose
and lactate oxidation and decreases fatty acid oxidation.
We observed a similar increase in LV pump function
without an increase in LV energy expenditure in response
to acute treatment with the fatty acid oxidation inhibitor
ranolazine in dogs with microembolization-induced HF
(53, 382).
In vitro studies demonstrate that high concentrations
of pyruvate increase contractile function and potentiate
the contractile effects of -adrenergic stimulation in nor-
mal myocardium (46, 160, 283) and in isolated samples of
failing human myocardium (151, 157, 161). Hermann et al.
(159) evaluated the effects of an acute intracoronary in-
fusion of sodium pyruvate on LV function in NYHA class
III HF patients with dilated cardiomyopathy (ejection
fraction 25%). The estimated pyruvate concentration in
the coronary artery was between 3 and 6 mM (well above
the normal levels of0.1 mM). Pyruvate infusion resulted
in a rapid increase in LV peak dP/dt, ejection fraction, and
cardiac output that immediately reversed upon cessation
of the infusion (158, 159). The mechanism for this re-
sponse is unclear but could be due to greater pyruvate
oxidation, increased cytosolic phosphorylation potential,
or effects on the Ca2 transient (151, 157, 161, 283). From
a practical standpoint, it is not feasible to intravenously
infuse sodium pyruvate to attain high arterial pyruvate
concentrations due to the high sodium load that accom-
panies infusion of the sodium salt. It is possible to avoid
this problem by infusing glycerol esters of pyruvate,
which was recently shown to elevate arterial pyruvate
concentrations and reduce myocardial infarct size during
reperfusion in pigs (432); however, this approach has not
been evaluated in HF.
Another means to rapidly enhance glucose oxidation
and inhibit fatty acid oxidation in humans is to raise
plasma insulin concentration. The effects of insulin on the
heart are complex in that insulin directly stimulates myo-
cardial glucose uptake (42, 194), but also dramatically
suppresses lipolysis in adipocytes and thus indirectly
stimulates myocardial glucose uptake and oxidation via
the Randle cycle (42, 108, 495). Cottin et al. (70) observed
an improved wall motion score and LV ejection fraction in
patients with ischemic heart disease and LV dysfunction
when they were treated with an infusion of insulin under
normoglycemic conditions (LV ejection fraction in-
creased from 38.1 6.4 to 53.3 11.6 after 1 h); however,
the study was not blinded, and there was no control
group. Nikolaidis et al. (326) recently demonstrated that a
continuous infusion of the insulinomimetic glucagon-like
peptide-1 (GLP-1) over a 2-day period improved LV func-
tion and increased myocardial glucose uptake in con-
scious dogs with advanced pacing-induced HF (326).
Moreover, treatment with GLP-1 increased myocardial
glucose uptake and increased LV mechanical efficiency
(327).
Taken together, there is evidence from small clinical
and animal studies to support the concept that acutely
stimulating myocardial carbohydrate oxidation and inhib-
iting myocardial fatty acid oxidation can rapidly improve
LV function and mechanical efficiency. The cellular mech-
anisms responsible for this effect are unclear but are
likely due to the various effects described in section IIF.
While the clinical data are intriguing, they are not defini-
tive, and large-scale controlled clinical trials are needed
before conclusions regarding clinical benefit can be
drawn.
B. Long-Term Metabolic Therapy to Slow Heart
Failure Progression and Improve Function
Chronic inhibition of myocardial FFA oxidation has
been investigated with the fatty acid oxidation inhibitor
trimetazidine (105) in HF patients (23, 115, 373) and ro-
dent models (88a, 446). Trimetazidine is an effective ge-
neric antianginal drug used extensively outside of North
America (78, 254, 427, 435, 445) and is a potent and
selective inhibitor of long-chain 3-ketoacyl thiolase (207,
268). In addition, studies in rats and isolated myocytes
show that trimetazidine alters myocardial phospholipid
metabolism, stimulating the turnover and accumulation of
long-chain fatty acids into phospholipid (413, 414), de-
creasing the fraction of phospholipids containing linoleic
acid, and increasing the content of phospholipids com-
prised of oleic and stearic acids (415). Studies in cardio-
myopathic Syrian hamsters (a HF model with severely
decreased PDH activity; Ref. 89) found that chronic treat-
ment with trimetazidine extended the average survival
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time on treatment from 364 to 560 days (88a). At the time
this study was performed, trimetazidine was not known to
be an inhibitor of fatty acid oxidation; therefore, the
relationship between metabolic alterations and HF pro-
gression was not investigated.
A small clinical trial showed that 2 mo of treatment
with trimetazidine resulted in significant improvement in
LV ejection fraction at rest and enhanced LV wall motion
during a dobutamine stress test compared with placebo in
NYHA classes II and III HF patients (23). In two recent
small clinical studies trimetazidine was shown to improve
systolic LV function in patients with diabetes and isch-
emic cardiomyopathy compared with placebo (115, 373).
Interestingly, 6 mo of trimetazidine improved diastolic
function, as assessed by an increase in the peak E/A ratio
on mitral flow (from 0.68  0.1 to 0.89  0.3), while there
was no change in the patients treated with placebo (373).
Trimetazidine has not been evaluated in patients with HF
from other than an ischemic origin, nor have large-scale
clinical trials been conducted.
Another approach to suppression of myocardial fatty
acid oxidation is inhibition of CPT-I. Studies by Rupp and
co-workers (376–378, 466, 515) demonstrated that
chronic treatment with etomoxir to rats with LV hyper-
trophy secondary to aortic banding results in improved LV
function and sarcoplasmic Ca2 handling, increased ex-
pression of SERCA2, and attenuated the transition from
compensated to failing cardiac hypertrophy. We recently
tested the hypothesis that pharmacological inhibition of
CPT-I with oxfenicine can prevent ventricular remodeling
and slow the progression of pacing-induced HF in dogs
(259). Treatment with oxfenicine significantly attenuated
LV dilation and hemodynamic dysfunction at 28 days of
pacing (Fig. 8) and significantly extended the duration of
pacing needed to reach terminal failure (LV end-diastolic
pressure  25 mmHg). In addition, oxfenicine completely
prevented LV wall thinning and the activation of matrix
metalloproteinases. Interestingly, inhibition of CPT-I re-
sulted in increased expression of PPAR- regulated genes
and prevented the HF-induced fall in the mRNA for met-
abolic enzymes. As recently noted by Rupp and co-work-
ers (378, 514), inhibition of CPT-I results in not only a
reduction in the rate of myocardial fatty acid oxidation,
but may also simultaneous stimulate the PPAR/RXR
complex through the build up of long-chain fatty acyl-CoA
in the cytosol. This could result in a paradoxical stimula-
tion of the expression of the enzymes of fatty acid oxida-
tion but decrease flux through the pathway. Rupp and
co-workers (377, 378) noted that inhibition of CPT-I in
rats with aortic banding partially prevented both the con-
tractile dysfunction and the downregulation of SERCA2,
which they speculated could be due to PPAR/RXR
regulation of SERCA2 expression, noting similarities be-
tween the SERCA2 regulatory region and the PPAR re-
sponse element (PPRE). Thus chronic inhibition of myo-
cardial fatty acid oxidation at the level of CPT-I in HF
could have very different results than a similar suppres-
sion of fatty acid oxidation with trimetazidine (which acts
directly on mitochondrial fatty acid -oxidation at the
level of long-chain 3-keto-acylthiolase). The effects of
CPT-I inhibition with etomoxir were assessed in an open
label pilot study in class II-III HF patients, showing im-
proved LV function and exercise performance following 3
mo of treatment (38, 405). The results of controlled trials
with CPT-I inhibitors have not been reported.
Conceptually, another means to switch substrate me-
tabolism would be to directly stimulate glucose uptake or
pyruvate oxidation; however, pharmacological agents are
not currently available for the chronic inhibition of PDK,
or activation of glucose transport or glycolysis. Studies in
transgenic mice provide insight for the potential for this
approach. Cardiac specific overexpression of GLUT-1 pre-
FIG. 8. Effects of the CPT-I inhibitor oxfenicine (60 mg/kg po once
daily) on left ventricular (LV) end-diastolic pressure (top) and end-
diastolic interventricular septal thickness (bottom) in dogs subjected to
rapid pacing-induced heart failure. Treatment was initiated on the first
day of pacing. *P  0.05 compared with baseline. †P  0.05 compared
with oxfenicine-treated group at the same time point. [Drawn from data
presented in Lionetti et al. (259).]
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vented LV dysfunction in response to ascending aortic
constriction and reduced mortality and depletion of high
energy phosphates (256), and GLUT-4 ablation in mice
results in LV hypertrophy (1). These results suggest that
pharmacological activation of carbohydrate oxidation has
potential as a drug target for the treatment of HF.
Dietary supplementation with either coenzyme Q or
carnitine has been proposed for the treatment of HF.
Acute and chronic administration of carnitine can in-
crease glucose oxidation in the isolated perfused rat heart
by increasing the acetylcarnitine concentration and de-
creasing the acetyl-CoA concentration, and thus relieving
acetyl-CoA inhibition on PDH (see Fig. 3) (40, 407). A
randomized double-blind trial in 472 myocardial infarc-
tion patients showed that oral carnitine therapy (6 g/day)
initiated within 24 h after the onset of chest pain failed to
effect clinical outcome or LV injection fraction over the
course of 1 yr of treatment; however, it did significantly
reduce the rate of increase in the LV end-diastolic volume
(187). Controlled trials in HF patients have not been
reported. The rationale for supplementation with coen-
zyme Q is that this will overcome possible lesions in the
ETC, as discussed in section IVB. While improved LV
function was suggested in small uncontrolled trials in HF
patients (191, 387), a double-blind crossover trial of oral
coenzyme Q versus placebo in 32 HF patients (LV ejection
fraction of 26%) showed that 3 mo with oral coenzyme Q
did not affect resting LV systolic function or the patient’s
quality of life despite more than a doubling of the plasma
levels of coenzyme Q (484).
Long-term -adrenergic receptor antagonists reduce
mortality and improve LV function in HF patients (39,
168), and in clinical studies this improvement is associ-
ated with a switch in myocardial metabolism away from
fatty acid uptake and oxidation towards more glucose
uptake and carbohydrate oxidation (100, 101, 480), and
greater lactate uptake (5). The mechanisms for these
effects are not known, nor have they been demonstrated
in large-scale clinical trials. We observed that 3 mo of
metoprolol treatment in dogs with coronary microembo-
lization-induced heart failure improved LV function and a
significant 28% decrease in CPT-I activity (337), suggest-
ing that the shift in substrate metabolism observed in the
clinical studies could be due to downregulation of this
enzyme.
Despite the clear beneficial effects of angiotensin
converting enzyme inhibitors and angiotensin receptor
antagonists in slowing the progression of HF, there are
little data on the metabolic consequences of suppression
of the effects of angiotensin in HF. Indirect measurement
of myocardial fatty acid metabolism using noninvasive
imaging of the fatty acid analog BMIPP shows that HF
patients have less cardiac accumulation of BMIPP and a
faster washout rate from the myocardium than in healthy
controls and that 6 mo of treatment with either enalipril
or candesartan improved cardiac function and increases
the accumulation and slows the rate of BMIPP washout
(450, 502), suggestive of greater fatty acid uptake and
clearance after treatment. The interpretation of these
findings is complicated by difficulties in quantitatively
relating BMIPP kinetics to myocardial fatty acid uptake
and oxidation (228, 234, 363). Nevertheless, these findings
are consistent with the idea that improvement in cardiac
function following chronic suppression of the renin-an-
giotensin system also alters myocardial fatty acid metab-
olism; however, it is not possible to draw a conclusion on
the nature of these alterations.
Studies in infarct-induced HF in the rat show a de-
crease in myocardial ATP and creatine phosphate and in
ADP stimulated respiration and that treatment with either
an angiotensin converting enzyme inhibitor or angioten-
sin receptor antagonist partially prevents this defect (397–
399). Lygate et al. (280) recently used this model to com-
pare the effects of chronic treatment with the PPAR
activator rosiglitazone, captopril, and rosiglitazone plus
captopril for 8 wk after infarction (280). LV ejection frac-
tion was moderately but significantly increased by rosigli-
tazone treatment, and the increase in LV end-diastolic
pressures and reduced dP/dt(max) was partially pre-
vented by rosiglitazone treatment either alone or in com-
bination with captopril. On the other hand, captopril pre-
vented LV dilatation when given alone or in combination
with rosiglitazone, while rosiglitozone alone did not. Im-
portantly, mortality at 8 wk was 26 and 19% for the
rosiglitazone and rosiglitazone plus captopril groups, re-
spectively. Clinically, PPAR agonists are associated with
edema in HF patients and are generally contraindicated
(455, 481). Further study is required before the effects of
pharmacological stimulation of the various PPARs on
cardiac function, remodeling, and progression in HF are
understood.
VI. CONCLUSIONS
The alterations in myocardial substrate metabolism
that occur in HF, and the causes and consequences of
these abnormalities, are poorly understood. There is evi-
dence to suggest that impaired substrate metabolism con-
tributes to contractile dysfunction and to the progressive
LV remodeling that are characteristic of the HF state. The
general concept that has recently emerged is that myo-
cardial substrate selection is relatively normal during the
early stages of HF; however, in the advanced stages there
is a downregulation in fatty acid oxidation, increased
glycolysis and glucose oxidation, reduced respiratory
chain activity, and an impaired reserve for mitochondrial
oxidative flux. While recent work has described many of
the molecular mechanisms responsible for the changes in
myocardial metabolic phenotype that occur during nor-
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mal physiology (e.g., maturation or fasting), we continue
to have a poor understanding of the regulatory mecha-
nisms that affect changes in the expression of metabolic
proteins over the course of HF. Initial pharmacological
studies suggest that manipulation of myocardial substrate
metabolism has therapeutic potential for the treatment of
HF. Taken together, we are just beginning to understand
the complex role of energy substrate metabolism in HF,
and there is a clear need for extensive work in this
clinically important area.
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